<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cytarabine (conventional): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cytarabine (conventional): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cytarabine (conventional): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9314" href="/d/html/9314.html" rel="external">see "Cytarabine (conventional): Drug information"</a> and <a class="drug drug_patient" data-topicid="12350" href="/d/html/12350.html" rel="external">see "Cytarabine (conventional): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708668"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Experienced physician:</span>
<div class="collapsible-wrap">
<p style="text-indent:-4em;margin-left:4em;">Only health care providers experienced in cancer chemotherapy should use cytarabine.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Drug toxicities:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">For induction therapy, patients should be treated in a facility with laboratory and supportive resources sufficient to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The main toxic effect of cytarabine is bone marrow suppression with leukopenia, thrombocytopenia, and anemia. Less serious toxicity includes nausea, vomiting, diarrhea and abdominal pain, oral ulceration, and hepatic dysfunction.</p>
<p style="text-indent:-2em;margin-left:2em;">The health care provider must judge possible benefit to the patient against known toxic effects of this drug in considering the advisability of therapy with cytarabine. Before making this judgment or beginning treatment, the health care provider should be familiar with the following text.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866484"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>PMS-Cytarabine</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1046767"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Antimetabolite</span></li></ul></div>
<div class="block dop drugH1Div" id="F156029"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing and frequency may vary by protocol and/or treatment phase; refer to specific protocol. In pediatric patients, IV dosing may be based on either BSA (mg/m<sup>2</sup>) or weight (mg/kg); use extra precaution to verify dosing parameters during calculations. Intrathecal dosing is based on the age of the patient. Antiemetics may be recommended to prevent nausea and vomiting. In pediatrics, a 75 mg/m<sup>2</sup> IV dose is associated with a moderate emetic potential and IV doses ≥3,000 mg/m<sup>2</sup> are associated with a high emetic potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30729654'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc96c63d-34bf-4494-9bfd-412032036264">Acute lymphocytic leukemia, B-cell</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute</b>
<b> lymphocytic leukemia, B-cell (B-ALL):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i> High risk B-ALL: </i> Limited data available, multiple regimens reported:</p>
<p style="text-indent:-2em;margin-left:6em;">Vrooman 2018 (DFCI 05-001): Intensified consolidation in very high-risk patients:</p>
<p style="text-indent:-2em;margin-left:8em;">Consolidation IB cycle: Children and Adolescents: IV: 75 mg/m<sup>2 </sup>once daily on days 2 through 5 and days 9 through 12 in combination with cyclophosphamide, 6-mercaptopurine, and intrathecal methotrexate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29941458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29941458'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Consolidation IC cycle: Children and Adolescents: IV: 2,000 mg/m<sup>2 </sup>every 12 hours for 4 doses beginning on day 1; administered in combination with etoposide, dexamethasone, and asparaginase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26549586','lexi-content-ref-29941458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26549586','lexi-content-ref-29941458'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Larsen 2016: Consolidation and delayed intensification I and II: Children and Adolescents: IV, SubQ: 75 mg/m<sup>2</sup> over 1 to 30 minutes or subcutaneous once daily for 4 days every 7 days for 2 courses; specific days depends on protocol phase.</p>
<p style="text-indent:-2em;margin-left:6em;">Steinherz 1993: NYII Protocol: Consolidation: Children and Adolescents: IV: 3,000 mg/m<sup>2</sup> over 3 hours for 4 doses on Days 28, 29, 35, and 36; experts at some centers have suggested fewer doses (eg, 2 doses).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i> Isolated CNS; relapse: </i>Limited data available; multiple regimens reported: Infants, Children, and Adolescents: IV: 300 mg/m<sup>2</sup>/dose; frequency dependent upon protocol.</p>
<p style="text-indent:-2em;margin-left:6em;">Ribeiro 1995, Rivera 1996: Children and Adolescents ≤14 years: Induction: Administer on Days 8, 22, 36; for Maintenance administer every 5 weeks for 52 weeks in combination with teniposide.</p>
<p style="text-indent:-2em;margin-left:6em;">Winick 1993: Continuation therapy: Infants, Children, and Adolescents: Administer on day 1 and 4 of week 7, 14, 21, 28, 35, 42, 49, and 56 in conjunction with teniposide.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a0616790-4d1f-431a-acc0-3bce79aef7bb">Acute myeloid leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia (AML):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Remission induction: </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">ADE regimen: Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25092781']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25092781'])">Ref</a></span>): <b>Note:</b> Some aspects of protocol dosing based on previous reports (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21766293','lexi-content-ref-21902686','lexi-content-ref-Guest.2014','lexi-content-ref-2205352']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21766293','lexi-content-ref-21902686','lexi-content-ref-Guest.2014','lexi-content-ref-2205352'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Induction 1 ADE (10 + 3 + 5) and Induction 2 ADE (8 + 3 + 5):</p>
<p style="text-indent:-2em;margin-left:10em;">Infants and Children with BSA &lt;0.6 m<sup>2</sup>: IV: 3.3 mg/<b>kg </b>over 1 to 30 minutes every 12 hours for 10 days (induction 1) or 8 days (induction 2) in combination with daunorubicin and etoposide.</p>
<p style="text-indent:-2em;margin-left:10em;">Children and Adolescents with BSA ≥0.6 m<sup>2</sup>: IV: 100 mg/m<sup>2</sup> over 1 to 30 minutes every 12 hours for 10 days (induction 1) or 8 days (induction 2) in combination with daunorubicin and etoposide.</p>
<p style="text-indent:-2em;margin-left:6em;">7 + 3 regimen: Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2205352']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2205352'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children &lt;3 years: IV: 3.3 mg/<b>kg</b>/day continuous infusion for 7 days; minimum of 2 courses (in combination with daunorubicin).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥3 years and Adolescents: IV: 100 mg/m<sup>2</sup>/day continuous infusion for 7 days; minimum of 2 courses (in combination with daunorubicin).</p>
<p style="text-indent:-2em;margin-left:6em;">Manufacturer's labeling: Manufacturer's labeling may not be reflective of current practice. Infants, Children, and Adolescents: IV: Standard dose: 100 mg/m<sup>2</sup>/day continuous infusion for 7 days or 200 mg/m<sup>2</sup>/day continuous infusion (as 100 mg/m<sup>2</sup>/dose over 12 hours every 12 hours) for 7 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Intensification: </i></b>Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25092781']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25092781'])">Ref</a></span>): <b>Note:</b> Some aspects of protocol dosing based on previous reports (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21766293','lexi-content-ref-21902686','lexi-content-ref-Guest.2014','lexi-content-ref-2205352']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21766293','lexi-content-ref-21902686','lexi-content-ref-Guest.2014','lexi-content-ref-2205352'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Intensification 1: AE therapy.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children with BSA &lt;0.6 m<sup>2</sup>: IV: 33 mg/<b>kg</b> over 1 hour every 12 hours for 5 days (in combination with etoposide).</p>
<p style="text-indent:-2em;margin-left:8em;">Children and Adolescents with BSA ≥0.6 m<sup>2</sup>: IV: 1,000 mg/m<sup>2</sup> over 1 hour every 12 hours for 5 days (in combination with etoposide).</p>
<p style="text-indent:-2em;margin-left:6em;">Intensification 2 (for patients not undergoing stem cell transplant): MA therapy:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children with BSA &lt;0.6 m<sup>2</sup>: IV: 33 mg/<b>kg</b> over 1 hour every 12 hours for 4 days (in combination with mitoxantrone).</p>
<p style="text-indent:-2em;margin-left:8em;">Children and Adolescents with BSA ≥0.6 m<sup>2</sup>: IV: 1,000 mg/m<sup>2</sup> over 1 hour every 12 hours for 4 days (in combination with mitoxantrone).</p>
<p style="text-indent:-2em;margin-left:6em;">Intensification 3 (for patients not undergoing stem cell transplant):</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children with BSA &lt;0.6 m<sup>2</sup>: IV: 99 mg/<b>kg</b> every 12 hours on days 1, 2, 8 and 9 in combination with <i>E. coli</i> L-asparaginase; <b>Note:</b> Some centers have substituted Erwinia asparaginase due to <i>E. coli</i> L-Asparaginase no longer being available.</p>
<p style="text-indent:-2em;margin-left:8em;">Children and Adolescents with BSA ≥0.6 m<sup>2</sup>: IV: 3,000 mg/m<sup>2</sup> every 12 hours on Days 1, 2, 8, and 9 in combination with <i>E. coli</i> L-asparaginase; <b>Note: </b>Some centers have substituted Erwinia asparaginase due to <i>E. coli</i> L-Asparaginase no longer being available.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Consolidation or refractory disease:</b></i> Limited data available: Capizzi II regimen (high-dose cytarabine [fixed]): Children ≥6 years and Adolescents: IV: 3,000 mg/m<sup>2</sup> over 3 hours every 12 hours for 4 doses, followed by <i>E. coli</i> L-Asparaginase (some centers have substituted<i> Erwinia asparaginase</i> due to <i>E. coli</i> L-Asparaginase no longer being available) 6 hours after the last dose of cytarabine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6696996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6696996'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Salvage treatment for refractory/recurrent disease:</i></b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:8em;">Clofarabine/cytarabine regimen: Children and Adolescents: IV: 1,000 mg/m<sup>2</sup> over 2 hours once daily for 5 days (in combination with clofarabine; administer cytarabine 4 hours after initiation of clofarabine) for up to 2 induction cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24771494']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24771494'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">FLAG regimen: Children ≥11 years and Adolescents: IV: 2,000 mg/m<sup>2</sup> over 4 hours once daily for 5 days (in combination with fludarabine and G-CSF); may repeat once if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9625576']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9625576'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">MEC regimen:</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥5 years and Adolescents: IV: 1,000 mg/m<sup>2</sup> over 6 hours for 6 days (in combination with etoposide and mitoxantrone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2045861']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2045861'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Adolescents ≥15 years: IV: 500 mg/m<sup>2</sup>/day continuous infusion days 1, 2, and 3 and days 8, 9, and 10 (in combination with mitoxantrone and etoposide); may administer a second course if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2018832','lexi-content-ref-7799010']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2018832','lexi-content-ref-7799010'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6d4c856e-dedc-4b57-9bc3-4eb783e31618">Non-Hodgkin lymphomas</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphomas:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i> Intermediate-risk B-cell NHL (Group B)</i>: Consolidation<i>:</i> R-CYM 1 and 2 regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22940833','lexi-content-ref-17132719']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22940833','lexi-content-ref-17132719'])">Ref</a></span>): Children and Adolescents: IV: 100 mg/m<sup>2</sup>/day as a continuous infusion over 24 hours on Days 2 through 6 (5 days; total dose: 500 mg/m<sup>2 </sup>as a 120-hour infusion) (in combination with rituximab and methotrexate).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>High-risk B-cell NHL (Group C):</i> Consolidation: R-CYVE 1 and 2 regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17138821','lexi-content-ref-11369626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17138821','lexi-content-ref-11369626'])">Ref</a></span>): Infants ≥6 months, Children, and Adolescents: IV: 50 mg/m<sup>2 </sup>infused over 12 hours (2000 to 0800) for 5 doses (Days 1 to 5); follow each 12-hour infusion dose with 3,000 mg/m<sup>2</sup> infused over 3 hours which starts at the end of the 12-hour infusion (0800 - 1100) x 5 doses (days 2 to 6) in combination with etoposide.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>B-lineage lymphoblastic lymphoma (B-LLy)</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23889312']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23889312'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Consolidation phase: Children and Adolescents: IV, SubQ: 75 mg/m<sup>2</sup> once daily for 4 days every 7 days for 4 courses (Days 0 to 3, 7 to 10, 14 to 17, 21 to 24).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed intensification: Children and Adolescents: IV, SubQ: 75 mg/m<sup>2</sup> once daily for 4 days every 7 days for 2 courses (Days 35 to 38 and 42 to 45).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="57b635dc-76c5-4bf4-bf33-a085cfa4c9e4">Meningeal leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningeal leukemia:</b> Infants, Children, and Adolescents: <b>Note: </b> Optimal intrathecal chemotherapy dosing should be based on age (see following information) rather than on body surface area (BSA); CSF volume correlates with age and not to BSA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6366138','lexi-content-ref-11248578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6366138','lexi-content-ref-11248578'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Age-based intrathecal fixed dosing: Intrathecal:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CNS prophylaxis (AML)</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2205352']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2205352'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;1 year: 20 mg per dose.</p>
<p style="text-indent:-2em;margin-left:8em;">1 to &lt;2 years: 30 mg per dose.</p>
<p style="text-indent:-2em;margin-left:8em;">2 to &lt;3 years: 50 mg per dose.</p>
<p style="text-indent:-2em;margin-left:8em;">≥3 years: 70 mg per dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CNS prophylaxis (ALL):</i> Dosing regimens variable, age-specific regimens reported from literature:</p>
<p style="text-indent:-2em;margin-left:8em;">Gaynon 1993: Administer on day 0 of induction therapy: Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:10em;">&lt;2 years: 30 mg per dose.</p>
<p style="text-indent:-2em;margin-left:10em;">2 to &lt;3 years: 50 mg per dose.</p>
<p style="text-indent:-2em;margin-left:10em;">≥3 years: 70 mg per dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Pieters 2007: Administer on day 15 of induction therapy, days 1 and 15 of reinduction phase; and day 1 of cycle 2 of maintenance 1A phase: Infants and young Children (≤12 months at enrollment):</p>
<p style="text-indent:-2em;margin-left:10em;">&lt;1 year: 15 mg per dose.</p>
<p style="text-indent:-2em;margin-left:10em;">≥1 year: 20 mg per dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Lin 2008: Administer as part of triple intrathecal therapy (TIT) on days 1 and 15 of induction therapy; days 1, 15, 50, and 64 (standard risk patients) or days 1, 15, 29, and 43 (high-risk patients) during consolidation therapy; day 1 of reinduction therapy, and during maintenance therapy (very high-risk patients receive on days 1, 22, 45, and 59 of induction, days 8, 22, 36, and 50 of consolidation therapy, days 8 and 38 of reinduction therapy, and during maintenance): Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:10em;">&lt;1 year: 18 mg per dose.</p>
<p style="text-indent:-2em;margin-left:10em;">1 to &lt;2 years: 24 mg per dose.</p>
<p style="text-indent:-2em;margin-left:10em;">2 to &lt;3 years: 30 mg per dose.</p>
<p style="text-indent:-2em;margin-left:10em;">≥3 years: 36 mg per dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment, CNS leukemia (ALL), Very high-risk:</i> Administer as part of triple intrathecal therapy (TIT) weekly until CSF remission, then every 4 weeks throughout continuation treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17455314']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17455314'])">Ref</a></span>): Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;1 year: 18 mg per dose.</p>
<p style="text-indent:-2em;margin-left:8em;">1 to &lt;2 years: 24 mg per dose.</p>
<p style="text-indent:-2em;margin-left:8em;">2 to &lt;3 years: 30 mg per dose.</p>
<p style="text-indent:-2em;margin-left:8em;">≥3 years: 36 mg per dose.</p>
<p style="text-indent:-2em;margin-left:4em;">BSA-directed intrathecal dosing: Manufacturer's labeling (based on BSA): Manufacturer's labeling may not reflect current practice: Intrathecal: 30 mg/m<sup>2</sup> every 4 days; range: 5 to 75 mg/m<sup>2</sup> once daily for 4 days or once every 4 days until CNS findings normalize, followed by one additional treatment.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51090498"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: There are no dosage adjustments provided in the manufacturer's labeling; however, the following guidelines have been used by some clinicians:</p>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Standard dosing range (100 to 200 mg/m<sup>2</sup>): No adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">High-dose cytarabine (1,000 to 3,000 mg/m<sup>2</sup>): There are no pediatric-specific recommendations; refer to specific protocols if available. Based on experience in adult patients, dosing adjustment suggested.</p></div>
<div class="block dohp drugH1Div" id="F51090499"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Dose may need to be adjusted in patients with liver failure since cytarabine is partially detoxified in the liver. There are no dosage adjustments provided in the manufacturer's labeling (refer to protocols); however, the following guidelines have been used by some clinicians: All patients:</p>
<p style="text-indent:-2em;margin-left:4em;">Floyd 2006: Transaminases (any elevation): Administer 50% of dose; may increase subsequent doses in the absence of toxicity, based primarily on experience in adult patients.</p>
<p style="text-indent:-2em;margin-left:4em;">Koren 1992 (dose not specified): Bilirubin &gt;2 mg/dL: Administer 50% of dose; may increase subsequent doses in the absence of toxicity, based on experience in adult patients.</p></div>
<div class="block doa drugH1Div" id="F156002"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9314" href="/d/html/9314.html" rel="external">see "Cytarabine (conventional): Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Antiemetics may be recommended to prevent nausea and vomiting; IV doses &gt;1,000 mg/m<sup>2</sup> are associated with a moderate emetic potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>). Consider hydration and antihyperuricemic therapy to prevent tumor lysis syndrome.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3b5fd58c-2ade-43ce-a3f5-be85a60e433f">Acute lymphoblastic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia (off-label dosing): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Induction regimen, relapsed or refractory: </i>
<b>IV:</b> 3,000 mg/m<sup>2</sup> over 3 hours daily for 5 days (in combination with idarubicin [day 3]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12209751']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12209751'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dose-intensive regimen: </i>
<b>IV:</b> 3,000 mg/m<sup>2</sup> over 2 hours every 12 hours days 2 and 3 (4 doses/cycle) of even numbered cycles (in combination with methotrexate; alternates with Hyper-CVAD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10653870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10653870'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CALGB 8811 regimen</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7718875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7718875'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Early-intensification phase: <b>SUBQ:</b> 75 mg/m<sup>2</sup>/dose days 1 to 4 and 8 to 11 (4-week cycle; repeat once).</p>
<p style="text-indent:-2em;margin-left:6em;">Late-intensification phase: <b>SUBQ: </b>75 mg/m<sup>2</sup>/dose days 29 to 32 and 36 to 39.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Linker protocol:</i> Adults &lt;50 years of age: <b>IV:</b> 300 mg/m<sup>2</sup>/day days 1, 4, 8, and 11 of even numbered consolidation cycles (in combination with teniposide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1835410']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1835410'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CALGB 10403 regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30658992']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30658992'])">Ref</a></span>) (as part of multi-agent, multicourse chemotherapy; refer to protocol for further details): </i></p>
<p style="text-indent:-2em;margin-left:6em;">Adults &lt;40 years of age:</p>
<p style="text-indent:-2em;margin-left:8em;">Remission consolidation phase (course 2): <b>IV, SUBQ: </b>75 mg/m<sup>2</sup> on days 1 to 4, 8 to 11, 29 to 32, and 36 to 39.</p>
<p style="text-indent:-2em;margin-left:8em;">Delayed intensification phase (course 4): <b>IV, SUBQ: </b>75 mg/m<sup>2</sup> on days 29 to 32 and 36 to 39.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24e0d924-5f00-4a6d-806e-6c7f7d725aad">Acute myeloid leukemia remission induction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia remission induction:</b> Standard-dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>); in combination with other chemotherapy agents): <b>IV: </b>100 mg/m<sup>2</sup>/day continuous infusion for 7 days <b>or</b> 200 mg/m<sup>2</sup>/day continuous infusion (as 100 mg/m<sup>2</sup> over 12 hours every 12 hours) for 7 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>7 + 3 regimens (a second induction course may be administered if needed; refer to specific references):</i>
<b>IV: </b>100 mg/m<sup>2</sup>/day continuous infusion for 7 days (in combination with daunorubicin <b>or</b> idarubicin <b>or</b> mitoxantrone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2179638','lexi-content-ref-1824249','lexi-content-ref-19776406','lexi-content-ref-1607916','lexi-content-ref-1730080']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2179638','lexi-content-ref-1824249','lexi-content-ref-19776406','lexi-content-ref-1607916','lexi-content-ref-1730080'])">Ref</a></span>) <b>or</b> (Adults &lt;60 years) 200 mg/m<sup>2</sup>/day continuous infusion for 7 days (in combination with daunorubicin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1824249']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1824249'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Low-intensity therapy (off-label dosing):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Adults ≥65 years of age: <b>SUBQ:</b> 20 mg/m<sup>2</sup>/day for 14 days out of every 28-day cycle for at least 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20026804']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20026804'])">Ref</a></span>) <b>or</b> 10 mg/m<sup>2</sup> every 12 hours for 21 days; if complete response not achieved, may repeat a second course after 15 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2299370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2299370'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults ≥60 years of age (and ineligible for intensive chemotherapy): <b>SUBQ</b>
<b>:</b> 20 mg/m<sup>2</sup> once daily on days 1 to 10 every 28 days (in combination with venetoclax) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32219442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32219442'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults ≥55 years of age (and unsuitable for intensive therapy): <b>SUBQ</b>
<b>:</b> 20 mg (flat dose) twice daily on days 1 to 10 every 28 days (in combination with glasdegib) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30555165']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30555165'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d2a5fab2-cfcf-42b7-9268-3c26566e4fdf">Acute myeloid leukemia consolidation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia consolidation (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>5 + 2 regimens:</i>
<b>IV: </b>100 mg/m<sup>2</sup>/day continuous infusion for 5 days (in combination with daunorubicin <b>or</b> idarubicin <b>or</b> mitoxantrone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2179638','lexi-content-ref-1730080']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2179638','lexi-content-ref-1730080'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>5 + 2 + 5 regimen:</i>
<b>IV: </b>100 mg/m<sup>2</sup>/day continuous infusion for 5 days (in combination with daunorubicin <b>and</b> etoposide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8634416']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8634416'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Single-agent:</i> Adults ≤60 years of age: <b>IV: </b>3,000 mg/m<sup>2</sup> over 3 hours every 12 hours on days 1, 3, and 5 (total of 6 doses); repeat every 28 to 35 days for 4 courses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8078551']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8078551'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="deb78d7a-f5cc-428b-8836-27a8de6ca102">Acute myeloid leukemia salvage treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute myeloid leukemia salvage treatment (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CLAG regimen: </i>
<b>IV: </b> 2,000 mg/m<sup>2</sup>/day over 4 hours for 5 days (in combination with cladribine and G-CSF); may repeat once if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12930315']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12930315'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CLAG-M regimen:</i>
<b>IV: </b> 2,000 mg/m<sup>2</sup>/day over 4 hours for 5 days (in combination with cladribine, G-CSF, and mitoxantrone); may repeat once if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18076637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18076637'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FLAG regimen: </i>
<b>IV: </b> 2,000 mg/m<sup>2</sup>/day over 4 hours for 5 days (in combination with fludarabine and G-CSF); may repeat once if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9625576']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9625576'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>GCLAC regimen:</i>
<b></b>Adults 18 to 70 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21848522']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21848522'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Induction</i>: <b>IV: </b>2,000 mg/m<sup>2</sup> over 2 hours once daily for 5 days (in combination with clofarabine and filgrastim; administer 4 hours after initiation of clofarabine); may repeat induction once if needed.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Consolidation:</i>
<b>IV: </b>1,000 mg/m<sup>2</sup> over 2 hours once daily for 5 days (in combination with clofarabine and filgrastim; administer 4 hours after initiation of clofarabine) for 1 or 2 cycles.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HiDAC (high-dose cytarabine) ± an anthracycline: </i>
<b>IV: </b> 3,000 mg/m<sup>2</sup> over 1 hour every 12 hours for 6 days (total of 12 doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3894588']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3894588'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>MEC regimen: </i>
<b>IV: </b> 1,000 mg/m<sup>2</sup>/day over 6 hours for 6 days (in combination with mitoxantrone and etoposide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2045861']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2045861'])">Ref</a></span>) <b>or</b></p>
<p style="text-indent:-2em;margin-left:6em;">Adults &lt;60 years of age: <b>IV: </b>500 mg/m<sup>2</sup>/day continuous infusion days 1, 2, and 3 and days 8, 9, and 10 (in combination with mitoxantrone and etoposide); may administer a second course if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2018832','lexi-content-ref-7799010']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2018832','lexi-content-ref-7799010'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b68fe5cb-a553-434f-83f5-132e418d1198">Acute promyelocytic leukemia induction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute promyelocytic leukemia induction (off-label dosing):</b>
<b>IV:</b> 200 mg/m<sup>2</sup>/day continuous infusion for 7 days beginning on day 3 of treatment (in combination with tretinoin and daunorubicin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17116939','lexi-content-ref-17975017','lexi-content-ref-20705755']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17116939','lexi-content-ref-17975017','lexi-content-ref-20705755'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8841e532-b640-4808-b4bb-b8991a3be86c">Acute promyelocytic leukemia consolidation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute promyelocytic leukemia consolidation (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with idarubicin and tretinoin:</i> High-risk patients (WBC ≥10,000/mm<sup>3</sup>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20393132']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20393132'])">Ref</a></span>): Adults ≤60 years of age:</p>
<p style="text-indent:-2em;margin-left:6em;">First consolidation course: <b>IV: </b>1,000 mg/m<sup>2</sup>/day for 4 days.</p>
<p style="text-indent:-2em;margin-left:6em;">Third consolidation course: <b>IV: </b>150 mg/m<sup>2</sup> every 8 hours for 4 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with idarubicin, tretinoin, and thioguanine:</i> High-risk patients (WBC &gt;10,000/mm<sup>3</sup>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20644121']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20644121'])">Ref</a></span>): Adults ≤61 years of age:</p>
<p style="text-indent:-2em;margin-left:6em;">First consolidation course: <b>IV: </b>1,000 mg/m<sup>2</sup>/day for 4 days.</p>
<p style="text-indent:-2em;margin-left:6em;">Third consolidation course: <b>IV: </b>150 mg/m<sup>2</sup> every 8 hours for 5 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>In combination with daunorubicin</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17116939','lexi-content-ref-17975017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17116939','lexi-content-ref-17975017'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">First consolidation course: <b>IV: </b>200 mg/m<sup>2</sup>/day for 7 days.</p>
<p style="text-indent:-2em;margin-left:6em;">Second consolidation course:</p>
<p style="text-indent:-2em;margin-left:8em;">Age ≤60 years and low risk (WBC &lt;10,000/mm<sup>3</sup>): <b>IV: </b>1,000 mg/m<sup>2</sup> every 12 hours for 4 days (8 doses).</p>
<p style="text-indent:-2em;margin-left:8em;">Age &lt;50 years and high risk (WBC ≥10,000/mm<sup>3</sup>): <b>IV: </b>2,000 mg/m<sup>2</sup> every 12 hours for 5 days (10 doses).</p>
<p style="text-indent:-2em;margin-left:8em;">Age 50 to 60 years and high risk (WBC ≥10,000/mm<sup>3</sup>): <b>IV: </b>1,500 mg/m<sup>2</sup> every 12 hours for 5 days (10 doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17975017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17975017'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Age &gt;60 years and high risk (WBC ≥10,000/mm<sup>3</sup>): <b>IV: </b>1,000 mg/m<sup>2</sup> every 12 hours for 4 days (8 doses).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1c2daff1-da41-460d-97f5-616d486189ba">Chronic lymphocytic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic lymphocytic leukemia (off-label use): </b>
<i>OFAR regimen:</i>
<b>IV:</b> 1,000 mg/m<sup>2</sup>/dose over 2 hours days 2 and 3 every 4 weeks for up to 6 cycles (in combination with oxaliplatin, fludarabine, and rituximab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18182662']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18182662'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4ebbaa33-8ab0-44b8-a662-fd68c7d18267">Hodgkin lymphoma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma, relapsed or refractory (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>DHAP regimen:</i>
<b>IV: </b>2,000 mg/m<sup>2</sup> over 3 hours every 12 hours day 2 (total of 2 doses/cycle) for 2 cycles (in combination with dexamethasone and cisplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12377653']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12377653'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ESHAP regimen:</i>
<b>IV: </b>2,000 mg/m<sup>2</sup> day 5 (in combination with etoposide, methylprednisolone, and cisplatin) every 3 to 4 weeks for 3 or 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10416011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10416011'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mini-BEAM regimen:</i>
<b>IV: </b>100 mg/m<sup>2</sup> every 12 hours days 2 to 5 (total of 8 doses) every 4 to 6 weeks (in combination with carmustine, etoposide, and melphalan) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7844600','lexi-content-ref-11328296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7844600','lexi-content-ref-11328296'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>BEAM regimen (transplant preparative regimen):</i>
<b>IV: </b>200 mg/m<sup>2</sup> twice daily for 4 days beginning 5 days prior to transplant (in combination with carmustine, etoposide, and melphalan) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8443375']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8443375'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6d4c856e-dedc-4b57-9bc3-4eb783e31618">Non-Hodgkin lymphomas</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphomas (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>BEAM regimen (transplant-preparative regimen):</i>
<b>IV: </b>200 mg/m<sup>2</sup> twice daily for 3 days beginning 4 days prior to transplant (in combination with carmustine, etoposide, and melphalan) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20201949']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20201949'])">Ref</a></span>) <b>or</b> 100 mg/m<sup>2</sup> over 1 hour every 12 hours for 4 days beginning 5 days prior to transplant (in combination with carmustine, etoposide, and melphalan) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15800666']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15800666'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Burkitt lymphoma: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CALGB 9251 regimen: </i>Cycles 2, 4, and 6: <b>IV: </b>150 mg/m<sup>2</sup>/day continuous infusion days 4 and 5 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11600602','lexi-content-ref-15042678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11600602','lexi-content-ref-15042678'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CODOX-M/IVAC regimen:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Adults ≤60 years of age: Cycles 2 and 4 (IVAC): <b>IV: </b>2,000 mg/m<sup>2</sup> every 12 hours days 1 and 2 (total of 4 doses/cycle) (IVAC is combination with ifosfamide, mesna, and etoposide; IVAC alternates with CODOX-M) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8622041']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8622041'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults ≤65 years of age: Cycles 2 and 4 (IVAC): <b>IV: </b>2,000 mg/m<sup>2</sup> over 3 hours every 12 hours days 1 and 2 (total of 4 doses/cycle) (IVAC is combination with ifosfamide, mesna, and etoposide; IVAC alternates with CODOX-M) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18612102']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18612102'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults &gt;65 years of age: Cycles 2 and 4 (IVAC): <b>IV: </b>1,000 mg/m<sup>2</sup> over 3 hours every 12 hours days 1 and 2 (total of 4 doses/cycle) (IVAC is combination with ifosfamide, mesna, and etoposide; IVAC alternates with CODOX-M) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18612102']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18612102'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hyper-CVAD alternating with high-dose methotrexate/cytarabine regimen: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Adults &lt;60 years of age: Cycles 2, 4, 6, and 8: <b>IV: </b>3,000 mg/m<sup>2</sup> every 12 hours days 2 and 3 (total of 4 doses/cycle) of a 21-day cycle (in combination with methotrexate and leucovorin), alternating with Hyper-CVAD administered on odd-numbered cycles (cyclophosphamide, vincristine, doxorubicin, and dexamethasone) plus rituximab (in cycles 1 to 4) and CNS prophylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16502413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16502413'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults ≥60 years of age: Cycles 2, 4, 6, and 8: <b>IV: </b>1,000 mg/m<sup>2</sup> every 12 hours days 2 and 3 (total of 4 doses/cycle) of a 21-day cycle (in combination with methotrexate and leucovorin) alternating with Hyper-CVAD administered on odd-numbered cycles (cyclophosphamide, vincristine, doxorubicin, and dexamethasone) with rituximab (in cycles 1 to 4) and CNS prophylaxis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16502413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16502413'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mantle cell lymphoma: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>R-DHAP regimen: </i>Adults ≤65 years of age: <b>IV: </b>2,000 mg/m<sup>2</sup> every 12 hours on day 2 (total of 2 doses/cycle) every 3 weeks (in combination with rituximab plus dexamethasone and cisplatin) for 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28953447']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28953447'])">Ref</a></span>) <b>or </b>2,000 mg/m<sup>2</sup> every 12 hours on day 2 (total of 2 doses/cycle; in combination with rituximab plus dexamethasone and cisplatin) alternating with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) for 6 cycles (3 cycles each of R-CHOP and R-DHAP) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27313086']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27313086'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>RBAC regimen:</i>
<b>IV: </b>500 to 800 mg/m<sup>2</sup> over 2 hours (starting 2 hours after bendamustine) on days 2 through 4 every 28 days for up to 6 cycles (in combination with rituximab and bendamustine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23401442','lexi-content-ref-27927586']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23401442','lexi-content-ref-27927586'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Nordic regimen:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Adults ≤60 years of age: <b>IV: </b>3,000 mg/m<sup>2</sup> over 3 hours every 12 hours for a total of 4 doses (in combination with rituximab) for 2 cycles alternating with Maxi-CHOP (dose-intensified CHOP) for 3 cycles (total of 5 cycles) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18625886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18625886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults &gt;60 years of age: <b>IV: </b>2,000 mg/m<sup>2</sup> over 3 hours every 12 hours for a total of 4 doses (in combination with rituximab) for 2 cycles alternating with Maxi-CHOP for 3 cycles (total of 5 cycles) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18625886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18625886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hyper-CVAD alternating with high-dose methotrexate/cytarabine regimen: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Adults ≤60 years of age: Cycles 2, 4, 6, and 8: <b>IV: </b>3,000 mg/m<sup>2</sup> every 12 hours days 3 and 4 (total of 4 doses/cycle) of a 21-day cycle (in combination with methotrexate, leucovorin, and rituximab), alternating with Hyper-CVAD administered on odd-numbered cycles (cyclophosphamide, vincristine, doxorubicin, dexamethasone, and rituximab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16145068']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16145068'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults &gt;60 years of age: Cycles 2, 4, 6, and 8: <b>IV: </b>1,000 mg/m<sup>2</sup> every 12 hours days 3 and 4 (total of 4 doses/cycle) of a 21-day cycle (in combination with methotrexate, leucovorin, and rituximab) alternating with Hyper-CVAD administered on odd-numbered cycles (cyclophosphamide, vincristine, doxorubicin, dexamethasone, and rituximab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16145068']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16145068'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Relapsed or refractory non-Hodgkin lymphomas: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>DHAP regimen:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Adults ≤70 years of age: <b>IV: </b>2,000 mg/m<sup>2</sup> over 3 hours every 12 hours day 2 (total of 2 doses/cycle) every 3 to 4 weeks for 6 to 10 cycles (in combination with dexamethasone and cisplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3334893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3334893'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults &gt;70 years of age: <b>IV: </b>1,000 mg/m<sup>2</sup> over 3 hours every 12 hours day 2 (total of 2 doses/cycle) every 3 to 4 weeks for 6 to 10 cycles (in combination with dexamethasone and cisplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3334893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3334893'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>ESHAP regimen:</i>
<b>IV: </b>2,000 mg/m<sup>2</sup> over 2 hours day 5 every 3 to 4 weeks for 6 to 8 cycles (in combination with etoposide, methylprednisolone, and cisplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8201379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8201379'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="742c866d-624d-41cf-a1cb-742554aedc03">Primary CNS lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary CNS lymphoma (off-label use): IV:</b> 2,000 mg/m<sup>2</sup> over 1 hour every 12 hours days 2 and 3 (total of 4 doses) every 3 weeks (in combination with methotrexate and followed by whole brain irradiation) for a total of 4 courses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19767089']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19767089'])">Ref</a></span>) <b>or </b>3,000 mg/m<sup>2 </sup>(maximum dose of 6,000 mg) over 3 hours on days 1 and 2 every 4 weeks for 2 cycles (administer cytarabine after 5 to 7 cycles of the induction R-MPV regimen [rituximab, methotrexate, leucovorin, vincristine, and procarbazine] and whole brain radiation therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17947720']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17947720'])">Ref</a></span>) <b>or</b> 2,000 mg/m<sup>2</sup> over 2 hours every 12 hours days 1 to 4 (total of 8 doses) as consolidation therapy (in combination with etoposide); cytarabine/etoposide is administered following remission induction with methotrexate, leucovorin, temozolomide, and rituximab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23569323']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23569323'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="57b635dc-76c5-4bf4-bf33-a085cfa4c9e4">Meningeal leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Meningeal leukemia: Intrathecal therapy:</b>
<b>Note:</b> Optimal intrathecal chemotherapy dosing should be based on age rather than on body surface area (BSA); CSF volume correlates with age and not to BSA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6366138','lexi-content-ref-11248578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6366138','lexi-content-ref-11248578'])">Ref</a></span>). Dosing provided in the manufacturer's labeling is BSA-based.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Off-label uses or doses for intrathecal therapy: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CNS prophylaxis (ALL):</i>
<b>Intrathecal: </b>100 mg weekly for 8 doses, then every 2 weeks for 8 doses, then monthly for 6 doses (high-risk patients) <b>or</b> 100 mg on day 7 or 8 with each chemotherapy cycle for 4 doses (low risk patients) <b>or</b> 16 doses (high-risk patients) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7662956']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7662956'])">Ref</a></span>) <b>or</b> 70 mg on day 1 of remission induction cycle 1 (adults &lt;40 years of age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30658992']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30658992'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>or</b> as part of intrathecal triple therapy (TIT): <b>Intrathecal: </b>40 mg days 0 and 14 during induction, days 1, 4, 8, and 11 during CNS therapy phase, every 18 weeks during intensification and maintenance phases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19438471']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19438471'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CNS prophylaxis (APL, as part of TIT):</i>
<b>Intrathecal: </b>50 mg per dose; administer 1 dose prior to consolidation and 2 doses during each of 2 consolidation phases (total of 5 doses) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17116939','lexi-content-ref-17975017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17116939','lexi-content-ref-17975017'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CNS prophylaxis (Burkitt lymphoma; component of CODOX-M/IVAC regimen):</i>
<b>Intrathecal: </b>70 mg on days 1 and 3 of cycles 1 and 3 (CODOX-M cycle) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8622041','lexi-content-ref-18612102']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8622041','lexi-content-ref-18612102'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CNS prophylaxis (Burkitt lymphoma; component of Hyper-CVAD alternating with cytarabine/methotrexate regimen):</i>
<b>Intrathecal: </b>100 mg on day 7 of each 21-day treatment cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16502413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16502413'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CNS leukemia treatment (ALL, as part of TIT):</i>
<b>Intrathecal: </b>40 mg twice weekly until CSF cleared (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19438471']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19438471'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CNS lymphoma treatment:</i>
<b>Intrathecal: </b>50 mg twice a week for 4 weeks, then weekly for 4 to 8 weeks, then every other week for 4 weeks, then every 4 weeks for 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10506606']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10506606'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CNS treatment (Burkitt lymphoma; component of CODOX-M/IVAC regimen):</i>
<b>Intrathecal: </b>70 mg on days 1, 3, and 5 of cycles 1 and 3 (CODOX-M cycle) and 70 mg on days 7 and 9 of cycles 2 and 4 (IVAC cycle) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8622041','lexi-content-ref-18612102']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8622041','lexi-content-ref-18612102'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Leptomeningeal metastases treatment</i>: <b>Intrathecal: </b>25 to 100 mg twice weekly for 4 weeks, then once weekly for 4 weeks, then a maintenance regimen of once a month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20689429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20689429'])">Ref</a></span>) <b>or</b> 40 to 60 mg per dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15813508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15813508'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992091"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Kenar D. Jhaveri, MD; Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Dose reductions for altered kidney function or those receiving kidney replacement therapies should not be applied to doses from treatment protocols where the dose has already been adjusted for age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sandhu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sandhu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Low-dose cytarabine (&lt;1,000 mg/m<sup>2</sup>/dose)</i>:</b> No dosage adjustment necessary for any degree of kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sandhu.1','lexi-content-ref-22212298']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sandhu.1','lexi-content-ref-22212298'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>High- and intermediate-dose cytarabine: (≥1,000 mg/m<sup>2</sup>/dose): </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Altered kidney function may increase the incidence of CNS toxicity with high-dose cytarabine treatment. Uracil arabinoside (Ara-U) may accumulate and inhibit cytidine deaminase, leading to increases of the neurotoxic metabolite aracytidine triphosphate (Ara-CTP); use with caution and consider reduced doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2778484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2778484'])">Ref</a></span>). Approaches to reduce the risk of neurotoxicity include dose adjustment for impaired renal function or decreasing the frequency of a twice-daily regimen to once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2778484','lexi-content-ref-9053511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2778484','lexi-content-ref-9053511'])">Ref</a></span>). The following dosage adjustments have been recommended:</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl ≥60 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sandhu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sandhu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 31 to 59 mL/minute: Consider alternative agents. If necessary, administer 50% of the usual recommended dose; monitor closely for neurotoxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sandhu.1','lexi-content-ref-30942181','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sandhu.1','lexi-content-ref-30942181','lexi-content-ref-Expert.DOR'])">Ref</a></span>). Some protocols cap single doses at 1,000 mg/m<sup>2 </sup>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15481055','lexi-content-ref-16145068','lexi-content-ref-9053511','lexi-content-ref-16502413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15481055','lexi-content-ref-16145068','lexi-content-ref-9053511','lexi-content-ref-16502413'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl ≤30 mL/minute: Consider alternative agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7859226','lexi-content-ref-30942181','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7859226','lexi-content-ref-30942181','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Regimen-specific or indication-specific dosage adjustment examples:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Cytarabine ≥2,000 mg/m<sup>2</sup>/dose (in acute myeloid leukemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9053511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9053511'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:8em;">Serum creatinine 1.5 to 1.9 mg/dL or increase (from baseline) of 0.5 to 1.2 mg/dL: Reduce dose to 1,000 mg/m<sup>2</sup>/dose, or alternatively, may consider changing administration from once every 12 hours to once every 24 hours and infuse over 3 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Serum creatinine ≥2 mg/dL or increase (from baseline) of &gt;1.2 mg/dL: Reduce dose to 100 mg/m<sup>2</sup>/day as a continuous infusion.</p>
<p style="text-indent:-2em;margin-left:6em;">Cytarabine 3,000 mg/m<sup>2</sup>/dose (studied in Burkitt or mantle cell lymphoma):</p>
<p style="text-indent:-2em;margin-left:8em;">Serum creatinine ≥1.5 mg/dL: Reduce dose to 1,000 mg/m<sup>2</sup>/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16145068','lexi-content-ref-16502413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16145068','lexi-content-ref-16502413'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (39% to 52% as Ara-U metabolite following administration of cytarabine 1,000 mg/m<sup>2</sup> IV over 2 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20532508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20532508'])">Ref</a></span>), dialyzability of Ara-CTP [active metabolite] is unknown). <b>Note:</b> Data are limited to case reports. Proceed with caution and only when no effective alternative treatments exist.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Low-dose cytarabine (&lt;1,000 mg/m<sup>2</sup>/dose)</i>:</b> No dosage adjustment necessary; may administer without regard to timing of dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21298312']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21298312'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>High- and intermediate-dose cytarabine (≥1,000 mg/m<sup>2</sup>/dose):</i></b> Consider alternative agents. If necessary, administer 50% of the usual recommended dose (max single dose: 1,000 mg/m<sup>2</sup>), dialysis should be started 2 to 6 hours after completion of the infusion to clear the Ara-U metabolite (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29385883','lexi-content-ref-31787588','lexi-content-ref-20532508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29385883','lexi-content-ref-31787588','lexi-content-ref-20532508'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b>
<b>Note:</b> Data are limited to a case report. Proceed with caution and only when no effective alternative treatments exist.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Low-dose cytarabine (&lt;1,000 mg/m<sup>2</sup>/dose)</i>: </b>Consider alternative agent because cytarabine (standard dose) plasma concentrations measured by radioimmunoassay in one adult undergoing CAPD were several-fold higher than reported concentrations evaluated in 265 adult subjects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7634384','lexi-content-ref-12627859']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7634384','lexi-content-ref-12627859'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>High- and intermediate-dose cytarabine (≥1,000 mg/m<sup>2</sup>/dose):</i></b> Consider alternative agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">No data exist for low-dose or high- and intermediate-dose cytarabine during CRRT. Given dialyzability of cytarabine and potential for reduced efficacy and/or increased toxicity, consider use of alternative drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">If use is deemed necessary: <b>IV, SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Low-dose cytarabine (&lt;1,000 mg/m<sup>2</sup>/dose)</i>: </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>High- and intermediate-dose cytarabine</i></b>
<b>
<i>(≥1,000 mg/m<sup>2</sup>/dose):</i></b> Administer 50% of the usual recommended dose (maximum single dose: 1,000 mg/m<sup>2</sup>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">No data exist for low-dose or high and intermediate-dose cytarabine during PIRRT. Given dialyzability of cytarabine and potential for reduced efficacy and/or increased toxicity, consider use of alternative drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">If use is deemed necessary: <b>IV, SUBQ:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Low-dose cytarabine (&lt;1,000 mg/m<sup>2</sup>/dose)</i>: </b>No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>High- and intermediate-dose cytarabine (≥1,000 mg/m<sup>2</sup>/dose):</i></b> Administer 50% of the dose (maximum single dose: 1,000 mg/m<sup>2</sup>). PIRRT should be started 2 to 6 hours after completion of the infusion to clear the Ara-U metabolite (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989307"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Dose may need to be adjusted in patients with liver failure since cytarabine is partially detoxified in the liver. Hepatic dysfunction may increase the incidence of CNS toxicity with high-dose cytarabine treatment; use with caution. There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended:</p>
<p style="text-indent:-2em;margin-left:2em;">Transaminases elevated (any elevation): Administer 50% of dose; may increase subsequent doses in the absence of toxicities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16473644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16473644'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Bilirubin &gt;2 mg/dL (dose level not specified): Administer 50% of dose; may increase subsequent doses in the absence of toxicities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1554959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1554959'])">Ref</a></span>).</p></div>
<div class="block adr drugH1Div" id="F155968"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Reported adverse reactions are for IV, SUBQ, or intrathecal administration of cytarabine with concomitant chemotherapeutic agents.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain, sinus bradycardia, thrombophlebitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, dermal ulcer, ephelis, pruritus, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, anorexia, diarrhea, esophageal ulcer, esophagitis, intestinal necrosis, nausea, oral inflammation, oral mucosa ulcer, proctocolitis, rectal ulcer, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary retention</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, bone marrow depression, hemorrhage, leukopenia, megaloblastic anemia, reticulocytopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic impairment, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Allergic angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Cellulitis at injection site, inflammation at injection site, pain at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, headache, leukoencephalopathy (necrotizing), neuritis, paralysis, paraplegia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blindness</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Kidney impairment</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea, pharyngitis, pneumonia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (includes adverse reactions with intermediate or high dose cytarabine):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocarditis (Pallazola 2018), pericarditis (Woods 1999)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Chiu 2002), maculopapular rash (Sahu 2019), skin rash (Forghieri 2007), toxicoderma (including ear redness [red ear syndrome] and palmar-plantar erythrodysesthesia) (Sahu 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperuricemia (Rudnick 1979)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Increased serum amylase (Yang 2020), increased serum lipase (Yang 2020), pancreatitis (including acute pancreatitis) (Yang 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes (Forghieri 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Rassiga 1980)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aseptic meningitis (Beaumont 2020), cerebellar syndrome (including ataxia, confusion, drowsiness, dysarthria, dysmetria, encephalitis, impaired consciousness, nystagmus disorder) (Lenfant 2021; Sainz de la Maza Cantero 2016), malaise (Sahu 2019), neurotoxicity (including peripheral neuropathy) (Malhotra 2004), reversible posterior leukoencephalopathy syndrome (Saito 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (Sahu 2019), ostealgia (Sahu 2019), rhabdomyolysis (Truica 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (Rudnick 1979), corneal toxicity (epithelial keratopathy) (Özcan 2021), keratoconjunctivitis (Cho 2018), uveitis (including anterior uveitis) (Cho 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary toxicity (including cryptogenic organizing pneumonia, hypoxemia, pulmonary edema, pulmonary infiltrates) (Forghieri 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (Rudnick 1979)</p></div>
<div class="block coi drugH1Div" id="F155982"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to cytarabine or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F155965"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Myelosuppression (leukopenia, thrombocytopenia, and anemia) is the major toxicity of cytarabine. Use with caution in patients with prior drug-induced bone marrow suppression. Infection or neutropenic fever due to neutropenia or bleeding due to thrombocytopenia may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cytarabine syndrome: Cytarabine (ARA-C) syndrome is characterized by fever, myalgia, bone pain, chest pain (occasionally), maculopapular rash, conjunctivitis, and malaise; generally occurs 6 to 12 hours following administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicities: Toxicities (less serious) include nausea, vomiting, diarrhea, abdominal pain, oral ulcerations, and hepatic dysfunction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Anaphylaxis resulting in acute cardiopulmonary arrest has been reported (rare).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pancreatitis: There have been reports of acute pancreatitis in patients receiving continuous infusion cytarabine and in patients receiving cytarabine who were previously treated with L-asparaginase.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sudden respiratory distress syndrome: Sudden respiratory distress, rapidly progressing to pulmonary edema and cardiomegaly, has been reported with high-dose cytarabine. May present as severe dyspnea with a rapid onset and refractory hypoxia with diffuse pulmonary infiltrates, leading to respiratory failure; may be fatal (Morgan 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">• Tumor lysis syndrome: Tumor lysis syndrome and subsequent hyperuricemia may occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Drug-drug interactions: There have been case reports of fatal cardiomyopathy when high-dose cytarabine was used in combination with cyclophosphamide as a preparation regimen for transplantation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Delayed progressive ascending paralysis has been reported in two children who received combination chemotherapy with IV and intrathecal cytarabine at conventional doses for the treatment of acute myeloid leukemia (was fatal in one patient).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol: Some products may contain benzyl alcohol; do not use products containing benzyl alcohol or products reconstituted with bacteriostatic diluent intrathecally or for high-dose cytarabine regimens. Benzyl alcohol is associated with gasping syndrome in premature infants.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Experienced providers: Administer under the supervision of experienced cancer chemotherapy providers. Due to the potential toxicities, induction treatment with cytarabine should be in a facility with sufficient laboratory and supportive resources.</p>
<p style="text-indent:-2em;margin-left:4em;">• High-dose treatment: High-dose regimens have been associated with GI, CNS, pulmonary, ocular (reversible corneal toxicity and hemorrhagic conjunctivitis; prophylaxis with ophthalmic corticosteroids is recommended) toxicities, and cardiomyopathy. Neurotoxicity associated with high-dose treatment may present as acute cerebellar toxicity (with or without cerebral impairment), personality changes, or may be severe with seizure and/or coma; may be delayed, occurring up to 3 to 8 days after treatment has begun; possibly irreversible. Risk factors for neurotoxicity include cumulative cytarabine dose, prior CNS disease and renal impairment (incidence may be up to 55% in patients with renal impairment); high-dose therapy (&gt;18 g/m<sup>2</sup> per cycle) and age &gt;50 years also increase the risk for cerebellar toxicity (Herzig 1987).</p>
<p style="text-indent:-2em;margin-left:4em;">• Intrathecal safety: When used for intrathecal administration, should not be prepared during the preparation of any other agents. After preparation, store intrathecal medications in an isolated location or container clearly marked with a label identifying as "intrathecal" use only. Delivery of intrathecal medications to the patient should only be with other medications also intended for administration into the CNS and administer immediately after a time-out/double-check procedure (ASCO/ONS [Neuss 2016]).</p></div>
<div class="block foc drugH1Div" id="F155976"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/mL (25 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/mL (5 mL, 50 mL); 100 mg/mL (20 mL)</p></div>
<div class="block geq drugH1Div" id="F155961"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323088"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Cytarabine (PF) Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $1.52 - $2.40</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/mL (per mL): $1.10 - $1.25</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Cytarabine Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $0.77</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866485"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/mL (5 mL, 25 mL); 100 mg/mL (1 mL, 10 mL, 20 mL)</p></div>
<div class="block admp drugH1Div" id="F52612473"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: <b>Note:</b> Antiemetics may be recommended to prevent nausea and vomiting. In pediatrics, a 75 mg/m<sup>2</sup> IV dose is associated with a moderate emetic potential and IV doses ≥3,000 mg/m<sup>2</sup> are associated with a high emetic potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30729654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IV infusion: May infuse as a continuous infusion over several hours (eg, 12 to 24 hours has been reported in pediatric trials) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17138821','lexi-content-ref-11369626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17138821','lexi-content-ref-11369626'])">Ref</a></span>). The manufacturer suggests continuous infusion of standard dose: 100 to 200 mg/m<sup>2</sup>/day. High-dose cytarabine has been infused over 1 to 3 hours according to protocols (refer to protocol) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6696996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6696996'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">IV Push: Administration over 15 to 30 minutes; has been reported in pediatric trials</p>
<p style="text-indent:-2em;margin-left:4em;">SubQ: May administer at concentration not to exceed 100 mg/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Allwood.2003']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Allwood.2003'])">Ref</a></span>); rotate injection sites; some centers have used thigh, abdomen, and flank regions</p>
<p style="text-indent:-2em;margin-left:2em;">Intrathecal administration: Antiemetic therapy should be administered prior to intrathecal doses of cytarabine. Administer as soon as possible after preparation.</p></div>
<div class="block adm drugH1Div" id="F155979"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse standard dose therapy for AML (100 to 200 mg/m<sup>2</sup>/day) as a continuous infusion. Infuse high-dose therapy (off-label) over 1 to 3 hours (usually). Other rates have been used, refer to specific reference.</p>
<p style="text-indent:-2em;margin-left:4em;">Antiemetics may be recommended to prevent nausea and vomiting; in adults, IV doses &gt;1,000 mg/m<sup>2</sup> are associated with a moderate emetic potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intrathecal:</b> Intrathecal doses should be administered as soon as possible after preparation.</p>
<p style="text-indent:-2em;margin-left:2em;">May also be administered SubQ.</p></div>
<div class="block hazard drugH1Div" id="F49130965"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block sts drugH1Div" id="F155991"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store intact vials at 20°C to 25°C (68°F to 77°F). Protect from light. Pharmacy bulk vials should be used within 4 hours of initial entry.</p>
<p style="text-indent:-2em;margin-left:2em;">IV infusion: Solutions for IV infusion diluted in D5W or NS retained 94% to 100% of potency after 8 days when stored at room temperature, although the manufacturer recommends administration as soon as possible after preparation.</p>
<p style="text-indent:-2em;margin-left:2em;">Intrathecal: Administer as soon as possible after preparation. After preparation, store intrathecal medications in an isolated location or container clearly marked with a label identifying as "intrathecal" use only.</p>
<p style="text-indent:-2em;margin-left:2em;">Follow USP 797 recommendations for beyond use dates based on the level of risk for preparation.</p></div>
<div class="block usep drugH1Div" id="F53566322"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Remission induction in acute myeloid leukemia (AML), treatment of acute lymphocytic leukemia (ALL) and chronic myelocytic leukemia (CML; blast phase) (FDA approved in pediatric patients [age not specified] and adults); has also been used in AML consolidation treatment, AML salvage treatment, and treatment of non-Hodgkin lymphomas (NHL) </p>
<p style="text-indent:-2em;margin-left:2em;">Intrathecal: Prophylaxis and treatment of meningeal leukemia (FDA approved in pediatric patients [age not specified] and adults)</p></div>
<div class="block mst drugH1Div" id="F156059"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cytarabine may be confused with cladribine, clofarabine, Cytosar, Cytoxan, daunorubicin and cytarabine (liposomal), vidarabine, vinorelbine</p>
<p style="text-indent:-2em;margin-left:4em;">Cytarabine (conventional) may be confused with cytarabine liposomal</p>
<p style="text-indent:-2em;margin-left:4em;">Cytarabine (conventional) (100 mg/5 mL; Hospira manufacturer) may be confused with vinorelbine (50 mg/5 mL; Hospira manufacturer) due to similar packaging; potential for inadvertent intrathecal administration of vinorelbine may occur (ISMP [Smetzer 2015]).</p>
<p style="text-indent:-2em;margin-left:4em;">Cytosar-U may be confused with cytarabine, Cytovene, Cytoxan, Neosar</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drugs classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<i>Intrathecal medication safety:</i> The American Society of Clinical Oncology (ASCO)/Oncology Nursing Society (ONS) chemotherapy administration safety standards (ASCO/ONS [Neuss 2016]) recommend the following safety measures for intrathecal chemotherapy:</p>
<p style="text-indent:-2em;margin-left:6em;">• Intrathecal medication should not be prepared during the preparation of any other agents.</p>
<p style="text-indent:-2em;margin-left:6em;">• After preparation, store in an isolated location or container clearly marked with a label identifying as "intrathecal" use only.</p>
<p style="text-indent:-2em;margin-left:6em;">• Delivery to the patient should only be with other medications also intended for administration into the central nervous system.</p>
<p style="text-indent:-2em;margin-left:6em;">• Administer immediately after a time-out/double-check procedure.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299114"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F155970"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cedazuridine: May increase the serum concentration of Cytidine Deaminase Substrates.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Agents that Undergo Intracellular Phosphorylation may diminish the therapeutic effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flucytosine: Cytarabine (Conventional) may diminish the therapeutic effect of Flucytosine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53539400"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients who could become pregnant should avoid becoming pregnant during treatment and be advised of the potential risks if exposure during pregnancy would occur.</p></div>
<div class="block pri drugH1Div" id="F155985"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and findings from animal reproduction studies, fetal harm may occur if cytarabine is administered during pregnancy. Limb and ear defects have been noted in case reports of cytarabine exposure during the first trimester of pregnancy. The following have also been noted in the neonate: Pancytopenia, WBC depression, electrolyte abnormalities, prematurity, low birth weight, decreased hematocrit or platelets. Risk to the fetus is decreased if treatment can be avoided during the first trimester.</p></div>
<div class="block mopp drugH1Div" id="F53566321"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Liver function tests, CBC with differential and platelet count, serum creatinine, BUN, serum uric acid; signs of neurotoxicity</p></div>
<div class="block pha drugH1Div" id="F155964"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Cytarabine inhibits DNA synthesis. Cytarabine gains entry into cells by a carrier process, and then must be converted to its active compound, aracytidine triphosphate. Cytarabine is a pyrimidine analog and is incorporated into DNA; however, the primary action is inhibition of DNA polymerase resulting in decreased DNA synthesis and repair. The degree of cytotoxicity correlates linearly with incorporation into DNA; therefore, incorporation into the DNA is responsible for drug activity and toxicity. Cytarabine is specific for the S phase of the cell cycle (blocks progression from the G<sub>1</sub> to the S phase).</p></div>
<div class="block phk drugH1Div" id="F155981"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Not effective when administered orally; less than 20% absorbed orally.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 3 ± 11.9 L/kg; total body water; widely and rapidly since it enters the cells readily; crosses blood-brain barrier with CSF levels of 40% to 50% of plasma level.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: SubQ: 89% to 100% (Leveque 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 13%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic; metabolized by deoxycytidine kinase and other nucleotide kinases to aracytidine triphosphate (Ara-CTP) (active); about 86% to 96% of dose is metabolized to inactive uracil arabinoside (Ara-U); intrathecal administration results in little conversion to Ara-U due to the low levels of deaminase in the cerebral spinal fluid.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: IV: Initial: 7 to 20 minutes; Terminal: 1 to 3 hours; Intrathecal: 2 to 6 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: SubQ: 20 to 60 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~80%; 90% as metabolite Ara-U) within 24 hours.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58843108"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Cytosar</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17116939">
<a name="17116939"></a>Adès L, Chevret S, Raffous, et al. Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group. <i>J Clin Oncol</i>. 2006;24(36):5703-5710.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/17116939/pubmed" id="17116939" target="_blank">17116939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17975017">
<a name="17975017"></a>Adès L, Sanz MA, Chevret S, et al. Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL): A Comparison of French-Belgian-Swiss and PETHEMA Results. <i>Blood</i>. 2008;111(3):1078-1084.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/17975017/pubmed" id="17975017" target="_blank">17975017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Allwood.2003">
<a name="Allwood.2003"></a>Allwood M, Stanley A. <i>The Cytotoxics Handbook</i>. 4th edition. Abingdon: Radcliffe Medical Press; 2003.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2045861">
<a name="2045861"></a>Amadori S, Arcese W, Isacchi G, et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. <i>J Clin Oncol</i>. 1991;9(7):1210-1214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/2045861/pubmed" id="2045861" target="_blank">2045861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10416011">
<a name="10416011"></a>Aparicio J, Segura A, Garcerá S, et al. ESHAP is an Active Regimen for Relapsing Hodgkin's Disease. <i>Ann Oncol</i>. 1999;10(5):593-595.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/10416011/pubmed" id="10416011" target="_blank">10416011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2018832">
<a name="2018832"></a>Archimbaud E, Leblond V, Michallet M, et al. Intensive Sequential Chemotherapy With Mitoxantrone and Continuous Infusion Etoposide and Cytarabine for Previously Treated Acute Myelogenous Leukemia. <i>Blood</i>. 1991;77(9):1894-1900.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/2018832/pubmed" id="2018832" target="_blank">2018832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7799010">
<a name="7799010"></a>Archimbaud E, Thomas X, Leblond V, et al. Timed Sequential Chemotherapy for Previously Treated Patients With Acute Myeloid Leukemia: Long-Term Follow-Up of the Etoposide, Mitoxantrone, and Cytarabine-86 Trial. <i>J Clin Oncol</i>. 1995;13(1):11-18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/7799010/pubmed" id="7799010" target="_blank">7799010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2179638">
<a name="2179638"></a>Arlin Z, Case DC Jr, Moore J, et al. Randomized Multicenter Trial of Cytosine Arabinoside With Mitoxantrone or Daunorubicin in Previously Untreated Adult Patients With Acute Nonlymphocytic Leukemia (ANLL). Lederle Cooperative Group. <i>Leukemia.</i> 1990;4(3):177-183.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/2179638/pubmed" id="2179638" target="_blank">2179638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. </i> 5th ed. American College of Physicians; 2007:98, 170.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21947834">
<a name="21947834"></a>Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2011;29(31):4189-4198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/21947834/pubmed" id="21947834" target="_blank">21947834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32702128">
<a name="32702128"></a>Beaumont AL, Suner L. Drug-induced aseptic meningitis in a Ph+ ALL patient with meningeal involvement. <i>Blood</i>. 2020;136(4):520. doi:10.1182/blood.2019004195<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/32702128/pubmed" id="32702128" target="_blank">32702128</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21848522">
<a name="21848522"></a>Becker PS, Kantarjian HM, Appelbaum FR, et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. <i>Br J Haematol</i>. 2011;155(2):182-189. doi:10.1111/j.1365-2141.2011.08831.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/21848522/pubmed" id="21848522" target="_blank">21848522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8634416">
<a name="8634416"></a>Bishop JF, Matthews JP, Young GA, et al. A Randomized Study of High-Dose Cytarabine in Induction in Acute Myeloid Leukemia. <i>Blood</i>. 1996;87(5):1710-1717.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/8634416/pubmed" id="8634416" target="_blank">8634416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6366138">
<a name="6366138"></a>Bleyer WA, Coccia PF, Sather HN, et al. Reduction in Central Nervous System Leukemia With a Pharmacokinetically Derived Intrathecal Methotrexate Dosage Regimen. <i>J Clin Oncol</i>. 1983;1(5):317-325.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/6366138/pubmed" id="6366138" target="_blank">6366138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8648381">
<a name="8648381"></a>Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. <i>J Clin Oncol</i>. 1996; 14(4):1252-1261.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/8648381/pubmed" id="8648381" target="_blank">8648381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24462742">
<a name="24462742"></a>Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee.<i> Biol Blood Marrow Transplant</i>. 2014;20(5):600-616. doi:10.1016/j.bbmt.2014.01.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/24462742/pubmed" id="24462742" target="_blank">24462742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23940227">
<a name="23940227"></a>Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. <i>J Clin Oncol</i>. 2013;31(27):3360-3368. doi:10.1200/JCO.2012.47.4874<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/23940227/pubmed" id="23940227" target="_blank">23940227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17138821">
<a name="17138821"></a>Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. <i>Blood</i>. 2007;109(7):2736-2743.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/17138821/pubmed" id="17138821" target="_blank">17138821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6696996">
<a name="6696996"></a>Capizzi RL, Poole M, Cooper MR, et al. Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase. <i>Blood</i>. 1984;63(3):694-700.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/6696996/pubmed" id="6696996" target="_blank">6696996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1780754">
<a name="1780754"></a>Capizzi RL, White JC, Powell BL, et al. Effect of Dose on the Pharmacokinetic and Pharmacodynamic Effects of Cytarabine. <i>Semin Hematol</i>. 1991;28(3)(suppl 4):54-69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/1780754/pubmed" id="1780754" target="_blank">1780754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9834301">
<a name="9834301"></a>Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy Compared With Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission. <i>N Engl J Med</i>. 1998;339(23):1649-1656.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/9834301/pubmed" id="9834301" target="_blank">9834301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20689429">
<a name="20689429"></a>Chamberlain MC. Leptomeningeal metastasis. <i>Curr Opin Oncol</i>. 2010;22(6):627-635.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/20689429/pubmed" id="20689429" target="_blank">20689429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6496516">
<a name="6496516"></a>Cheung YW, Vishnuvajjala BR, Flora KP. Stability of cytarabine, methotrexate sodium, and hydrocortisone sodium succinate admixtures. <i>Am J Hosp Pharm</i>. 1984;41(9):1802-1806.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/6496516/pubmed" id="6496516" target="_blank">6496516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12271319">
<a name="12271319"></a>Chiu A, Kohler S, McGuire J, et al. Cytarabine-induced acute generalized exanthematous pustulosis. <i>J Am Acad Dermatol</i>. 2002;47(4):633-635.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/12271319/pubmed" id="12271319" target="_blank">12271319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29359539">
<a name="29359539"></a>Cho AR, Yoon YH, Kim JG, Kim YJ, Lee JY. Uveoretinal adverse effects presented during systemic anticancer chemotherapy: a 10-year single center experience. <i>J Korean Med Sci</i>. 2018;33(7):e55. doi:10.3346/jkms.2018.33.e55<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/29359539/pubmed" id="29359539" target="_blank">29359539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8443375">
<a name="8443375"></a>Chopra R, McMillan AK, Linch DC, et al .The Place of High-Dose BEAM Therapy and Autologous Bone Marrow Transplantation in Poor-Risk Hodgkin's Disease. A Single-Center Eight-Year Study of 155 Patients. <i>Blood</i>. 1993;81(5):1137-1145.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/8443375/pubmed" id="8443375" target="_blank">8443375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7844600">
<a name="7844600"></a>Colwill R, Crump M, Couture F, et al. Mini-BEAM as Salvage Therapy for Relapsed or Refractory Hodgkin's Disease Before Intensive Therapy and Autologous Bone Marrow Transplantation. <i>J Clin Oncol</i>. 1995;13(2):396-402.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/7844600/pubmed" id="7844600" target="_blank">7844600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24771494">
<a name="24771494"></a>Cooper TM, Alonzo TA, Gerbing RB, et al. AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. <i>Cancer</i>. 2014;120(16):2482-2489. doi:10.1002/cncr.28674<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/24771494/pubmed" id="24771494" target="_blank">24771494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21766293">
<a name="21766293"></a>Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. <i>Cancer</i>. 2012;118(3):761-769.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/21766293/pubmed" id="21766293" target="_blank">21766293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30555165">
<a name="30555165"></a>Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Leukemia</i>. 2019;33(2):379-389. doi:10.1038/s41375-018-0312-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/30555165/pubmed" id="30555165" target="_blank">30555165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7662956">
<a name="7662956"></a>Cortes J, O’Brien SM, Pierce S, et al. The Value of High-Dose Systemic Chemotherapy and Intrathecal Therapy for Central Nervous System Prophylaxis in Different Risk Groups of Adult Acute Lymphoblastic Leukemia. <i>Blood</i>. 1995;86(6):2091-2097.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/7662956/pubmed" id="7662956" target="_blank">7662956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cytarabine.3">
<a name="Cytarabine.3"></a>Cytarabine 20 mg/mL 5mL PF single dose vial [prescribing information]. Schaumburg, IL: Sagent Pharmaceuticals; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cytarabine.4">
<a name="Cytarabine.4"></a>Cytarabine 100 mg/mL 20mL PF single dose vial [prescribing information]. Schaumburg, IL: Sagent Pharmaceuticals; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cytarabine.1">
<a name="Cytarabine.1"></a>Cytarabine 20 mg/mL 25 mL multiple-dose vial (benzyl alcohol) [prescribing information]. Lake Forest, IL: Hospira; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cytarabine.2">
<a name="Cytarabine.2"></a>Cytarabine bulk package [prescribing information]. Lake Forest, IL: Hospira; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2778484">
<a name="2778484"></a>Damon LE, Mass R, Linker CA. The association between high-dose cytarabine neurotoxicity and renal insufficiency. <i>J Clin Oncol</i>. 1989;7(10):1563-1568. doi:10.1200/JCO.1989.7.10.1563<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/2778484/pubmed" id="2778484" target="_blank">2778484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15813508">
<a name="15813508"></a>DeAngelis LM, Boutros D. Leptomeningeal Metastasis. <i>Cancer Invest</i>. 2005;23(2):145-154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/15813508/pubmed" id="15813508" target="_blank">15813508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18772215">
<a name="18772215"></a>de Lemos ML, Monfared S, Denyssevych T, et al. Evaluation of Osmolality and pH of Various Concentrations of Methotrexate, Cytarabine, and Thiotepa Prepared in Normal Saline, Sterile Water for Injection, and Lactated Ringers’s Solution for Intrathecal Administration. <i>J Oncol Pharm Pract</i>. 2009;15(1):45-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/18772215/pubmed" id="18772215" target="_blank">18772215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1824249">
<a name="1824249"></a>Dillman RO, Davis RB, Green MR, et al. A Comparative Study of Two Different Doses of Cytarabine for Acute Myeloid Leukemia: A Phase III Trial of Cancer and Leukemia Group B. <i>Blood</i>. 1991;78(10):2520-2526.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/1824249/pubmed" id="1824249" target="_blank">1824249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19880497">
<a name="19880497"></a>Döhner H, Estey EH, Amadori S, et al. Diagnosis and Management of Acute Myeloid Leukemia in Adults: Recommendations From an International Expert Panel, on Behalf of the European LeukemiaNet. <i>Blood</i>. 2010;115(3):453-474.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/19880497/pubmed" id="19880497" target="_blank">19880497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21465637">
<a name="21465637"></a>Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/21465637/pubmed" id="21465637" target="_blank">21465637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23512831">
<a name="23512831"></a>Dupuis LL, Boodhan S, Holdsworth M, et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/23512831/pubmed" id="23512831" target="_blank">23512831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29385883">
<a name="29385883"></a>Ettleson M, Bongers KS, Vitale K, Perissinotti AJ, Phillips T, Marini BL. Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: a case report. <i>J Oncol Pharm Pract</i>. 2019;25(3):731-734. doi:10.1177/1078155217754244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/29385883/pubmed" id="29385883" target="_blank">29385883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Kenar D. Jhaveri, MD; Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20026804">
<a name="20026804"></a>Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. <i>J Clin Oncol</i>. 2010;28(4):562-569. doi:10.1200/JCO.2009.23.8329<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/20026804/pubmed" id="20026804" target="_blank">20026804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19776406">
<a name="19776406"></a>Fernandez HF, Sun Z, Yao X, et al. Anthracycline Dose Intensification in Acute Myeloid Leukemia. <i>N Engl J Med</i>. 2009;361(13):1249-1259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/19776406/pubmed" id="19776406" target="_blank">19776406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19767089">
<a name="19767089"></a>Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. <i>Lancet.</i> 2009;374(9700):1512-1520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/19767089/pubmed" id="19767089" target="_blank">19767089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7634384">
<a name="7634384"></a>Fleming RA, Capizzi RL, Rosner GL, et al. Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study. <i>Cancer Chemother Pharmacol</i>. 1995;36(5):425-430. doi:10.1007/BF00686192<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/7634384/pubmed" id="7634384" target="_blank">7634384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16473644">
<a name="16473644"></a>Floyd J, Mirza I, Sachs B, et al. Hepatotoxicity of Chemotherapy. <i>Semin Oncol</i>. 2006;33(1):50-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/16473644/pubmed" id="16473644" target="_blank">16473644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16234530">
<a name="16234530"></a>Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of Cancer Therapy. <i>J Clin Oncol</i>, 2005;23(30):7685-7696. doi:10.1200/JCO.2005.08.789<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/16234530/pubmed" id="16234530" target="_blank">16234530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17768138">
<a name="17768138"></a>Forghieri F, Luppi M, Morselli M, Potenza L. Cytarabine-related lung infiltrates on high resolution computerized tomography: a possible complication with benign outcome in leukemic patients. <i>Haematologica</i>. 2007;92(9):e85-e90. doi:10.3324/haematol.11697<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/17768138/pubmed" id="17768138" target="_blank">17768138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25092781">
<a name="25092781"></a>Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. <i>J Clin Oncol</i>. 2014;32(27):3021-3032.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/25092781/pubmed" id="25092781" target="_blank">25092781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17341661">
<a name="17341661"></a>Gardin C, Turlure P, Fagot T, et al. Postremission Treatment of Elderly Patients With Acute Myeloid Leukemia in First Complete Remission After Intensive Induction Chemotherapy: Results of the Multicenter Randomized Acute Leukemia French Association (ALFA) 9803 Trial. <i>Blood</i>. 2007;109(12):5129-5135.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/17341661/pubmed" id="17341661" target="_blank">17341661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8229139">
<a name="8229139"></a>Gaynon PS, Steinherz PG, Bleyer WA, et al. Improved Therapy for Children With Acute Lymphoblastic Leukemia and Unfavorable Presenting Features: A Follow-Up Report of the Childrens Cancer Group Study CCG-106. <i>J Clin Oncol</i>. 1993;11(11):2234-2242.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/8229139/pubmed" id="8229139" target="_blank">8229139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18625886">
<a name="18625886"></a>Geisler CH, Kolstad A, Laurell A, et al; Nordic Lymphoma Group. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. <i>Blood</i>. 2008;112(7):2687-2693. doi:10.1182/blood-2008-03-147025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/18625886/pubmed" id="18625886" target="_blank">18625886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21902686">
<a name="21902686"></a>Gibson BE, Webb DK, Howman AJ, et al. Results of a randomized trial in children with acute myeloid leukaemia: medical research council AML12 trial. <i>Br J Haematol</i>. 2011;155(3):366-376.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/21902686/pubmed" id="21902686" target="_blank">21902686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10506606">
<a name="10506606"></a>Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis. <i>J Clin Oncol</i>. 1999;17(10):3110-3116.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/10506606/pubmed" id="10506606" target="_blank">10506606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22940833">
<a name="22940833"></a>Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. <i>Leukemia.</i> 2013;27(5):1174-1177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/22940833/pubmed" id="22940833" target="_blank">22940833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Guest.2014">
<a name="Guest.2014"></a>Guest EM, Aplenc R, Sung L, et al. Gemtuzumab ozogamicin (GO) in infants with acute myeloid leukemia (AML) - combined results from the Children's Oncology Group (COG) trials. AAML03P1 and AAML0531. <i>Blood</i>. 2014;124:377.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9227927">
<a name="9227927"></a>Guilhot F, Chastang C, Michallet M, et al. Interferon Alfa-2b Combined With Cytarabine Versus Interferon Alone in Chronic Myelogenous Leukemia. French Chronic Myeloid Leukemia Study Group. <i>N Engl J Med</i>. 1997;337(4):223-229.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/ 9227927/pubmed" id=" 9227927" target="_blank"> 9227927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27313086">
<a name="27313086"></a>Hermine O, Hoster E, Walewski J, et al; European Mantle Cell Lymphoma Network. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. <i>Lancet</i>. 2016;388(10044):565-575. doi:10.1016/S0140-6736(16)00739-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/27313086/pubmed" id="27313086" target="_blank">27313086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3585447">
<a name="3585447"></a>Herzig RH, Hines JD, Herzig GP, et al. Cerebellar Toxicity With High-Dose Cytosine Arabinoside. <i>J Clin Oncol</i>. 1987;5(6):927-932.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/3585447/pubmed" id="3585447" target="_blank">3585447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3894588">
<a name="3894588"></a>Herzig RH, Lazarus HM, Wolff SN, et al. High-Dose Cytosine Arabinoside Therapy With and Without Anthracycline Antibiotics for Remission Reinduction of Acute Nonlymphoblastic Leukemia. <i>J Clin Oncol</i>. 1985;3(7):992-997.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/3894588/pubmed" id="3894588" target="_blank">3894588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2031974">
<a name="2031974"></a>Hiddemann W. Cytosine Arabinoside in the Treatment of Acute Myeloid Leukemia: The Role and Place of High-Dose Regimens. <i>Ann Hematol</i>. 1991;62(4):119-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/2031974/pubmed" id="2031974" target="_blank">2031974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12377653">
<a name="12377653"></a>Josting A, Rudolph C, Reiser M, et al. Time-Intensified Dexamethasone/Cisplatin/Cytarabine: An Effective Salvage Therapy With Low Toxicity in Patients With Relapsed and Refractory Hodgkin's Disease. <i>Ann Oncol</i>. 2002;13(10):1628-1635.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/12377653/pubmed" id="12377653" target="_blank">12377653</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15481055">
<a name="15481055"></a>Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. <i>Cancer</i>. 2004;101(12):2788-2801. doi:10.1002/cncr.20668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/15481055/pubmed" id="15481055" target="_blank">15481055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10653870">
<a name="10653870"></a>Kantarjian HM, O'Brien S, Smith TL, et al. Results of Treatment With Hyper-CVAD, A Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia. <i>J Clin Oncol</i>. 2000;18(3):547-561.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/10653870/pubmed" id="10653870" target="_blank">10653870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11248578">
<a name="11248578"></a>Kerr JZ, Berg S, Blaney SM. Intrathecal Chemotherapy. <i>Crit Rev Oncol Hematol</i>. 2001;37(3):227-236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/11248578/pubmed" id="11248578" target="_blank">11248578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7859226">
<a name="7859226"></a>Kintzel PE, Dorr RT. Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function. <i>Cancer Treat Rev</i>. 1995;21(1):33-64. doi:10.1016/0305-7372(95)90010-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/7859226/pubmed" id="7859226" target="_blank">7859226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1554959">
<a name="1554959"></a>Koren G, Beatty K, Seto A, Einarson TR, Lishner M. The Effects of Impaired Liver Function on the Elimination of Antineoplastic Agents. <i>Ann Pharmacother</i>. 1992;26(3):363-371. doi:10.1177/106002809202600311<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/1554959/pubmed" id="1554959" target="_blank">1554959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22212298">
<a name="22212298"></a>Krogh-Madsen M, Bender B, Jensen MK, Nielsen OJ, Friberg LE, Honoré PH. Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia. <i>Cancer Chemother Pharmacol</i>. 2012;69(5):1155-1163. doi:10.1007/s00280-011-1800-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/22212298/pubmed" id="22212298" target="_blank">22212298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8083715">
<a name="8083715"></a>Land VJ, Shuster JJ, Crist WM, et al. Comparison of Two Schedules of Intermediate-Dose Methotrexate and Cytarabine Consolidation Therapy for Childhood B-Precursor Cell Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Study. <i>J Clin Oncol</i>. 1994;12(9):1939-1945.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/8083715/pubmed" id="8083715" target="_blank">8083715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27114587">
<a name="27114587"></a>Larsen EC, Devidas M, Chen s, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children's Oncology Group Study AALL0232. <i>J Clin Oncol</i>. 2016;34(20):2380-2388.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/27114587/pubmed" id="27114587" target="_blank">27114587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7718875">
<a name="7718875"></a>Larson RA, Dodge RK, Burns CP, et al. A Five-Drug Remission Induction Regimen With Intensive Consolidation for Adults With Acute Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8811. <i>Blood</i>. 1995;85(8):2025-2037.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/7718875/pubmed" id="7718875" target="_blank">7718875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28953447">
<a name="28953447"></a>Le Gouill S, Thieblemont C, Oberic L, et al; LYSA Group. rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. <i>N Engl J Med</i>. 2017;377(13):1250-1260. doi:10.1056/NEJMoa1701769<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/28953447/pubmed" id="28953447" target="_blank">28953447</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11600602">
<a name="11600602"></a>Lee EJ, Petroni GR, Schiffer CA, et al. Brief-Duration High-Intensity Chemotherapy for Patients With Small Noncleaved-Cell Lymphoma or FAB L3 Acute Lymphocytic Leukemia: Results of Cancer and Leukemia Group B Study 9251. <i>J Clin Oncol</i>. 2001;19(20):4014-4022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/11600602/pubmed" id="11600602" target="_blank">11600602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34611580">
<a name="34611580"></a>Lenfant C, Greiner N, Duprez T. Cytarabine-induced encephalitis. <i>J Belg Soc Radiol</i>. 2021;105(1):46. doi:10.5334/jbsr.2492<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/34611580/pubmed" id="34611580" target="_blank">34611580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24692685">
<a name="24692685"></a>Leveque D. Subcutaneous administration of anticancer agents. <i>Anticancer Res</i>. 2014;34(4):1579-1586.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/24692685/pubmed" id="24692685" target="_blank">24692685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17455314">
<a name="17455314"></a>Lin WY, Liu HC, Yeh TC, et al. Triple Intrathecal Therapy Without Cranial Irradiation for Central Nervous System Preventive Therapy in Childhood Acute Lymphoblastic Leukemia. <i>Pediatr Blood Cancer</i>. 2008;50(3):523-527.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/17455314/pubmed" id="17455314" target="_blank">17455314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20201949">
<a name="20201949"></a>Linch DC, Yung L, Smith P, et al. Final Analysis of the UKLG LY02 Trial Comparing 6-8 Cycles of CHOP With 3 Cycles of CHOP Followed by a BEAM Autograft in Patients &lt;65 Years With Poor Prognosis Histologically Aggressive NHL. <i>Br J Haematol</i>. 2010;149(2):237-243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/20201949/pubmed" id="20201949" target="_blank">20201949</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1835410">
<a name="1835410"></a>Linker CA, Levitt LJ, O'Donnell M, et al. Treatment of Adult Acute Lymphoblastic Leukemia With Intensive Cyclical Chemotherapy: A Follow-up Report. <i>Blood</i>. 1991;78(11):2814-2822.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/1835410/pubmed" id="1835410" target="_blank">1835410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20644121">
<a name="20644121"></a>Lo Coco F, Avvisati G, Vignetti M, et al. Front-Line Treatment of Acute Promyelocytic Leukemia With AIDA Induction Followed by Risk-Adapted Consolidation for Adults Younger Than 61 Years: Results of the AIDA-2000 Trial of the GIMEMA Group. <i>Blood</i>. 2010;116(17):3171-3179.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/20644121/pubmed" id="20644121" target="_blank">20644121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21410371">
<a name="21410371"></a>Löwenberg B, Pabst T, Vellenga E, et al. Cytarabine Dose for Acute Myeloid Leukemia. <i>N Engl J Med</i>. 2011;364(11):1027-1036.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/21410371/pubmed" id="21410371" target="_blank">21410371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8622041">
<a name="8622041"></a>Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. <i>J Clin Oncol</i>. 1996;14(3):925-934. doi:10.1200/JCO.1996.14.3.925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/8622041/pubmed" id="8622041" target="_blank">8622041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15551283">
<a name="15551283"></a>Malhotra P, Mahi S, Lal V, Kumari S, Jain S, Varma S. Cytarabine-induced neurotoxicity responding to methyl prednisolone. <i>Am J Hematol</i>. 2004;77(4):416. doi:10.1002/ajh.20171<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/15551283/pubmed" id="15551283" target="_blank">15551283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11328296">
<a name="11328296"></a>Martín A, Fernández-Jiménez MC, Caballero MD, et al. Long-Term Follow-Up in Patients Treated With Mini-BEAM as Salvage Therapy for Relapsed or Refractory Hodgkin's Disease. <i>Br J Haematol</i>. 2001;113(1):161-171.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/11328296/pubmed" id="11328296" target="_blank">11328296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16609069">
<a name="16609069"></a>Matloub Y, Lindemulder S, Gaynon PS, et al. Intrathecal Triple Therapy Decreases Central Nervous System Relapse but Fails to Improve Event-Free Survival When Compared With Intrathecal Methotrexate: Results of the Children's Cancer Group (CCG) 1952 Study for Standard-Risk Acute Lymphoblastic Leukemia, Reported by the Children's Oncology Group. <i>Blood</i>. 2006;108(4):1165-1173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/16609069/pubmed" id="16609069" target="_blank">16609069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8078551">
<a name="8078551"></a>Mayer RJ, Davis RB, Schiffer CA, et al. Intensive Postremission Chemotherapy in Adults With Acute Myeloid Leukemia, Cancer and Leukemia Group B. <i>N Engl J Med</i>. 1994;331(14):896-903.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/8078551/pubmed" id="8078551" target="_blank">8078551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18612102">
<a name="18612102"></a>Mead GM, Barrans SL, Qian W, et al; UK National Cancer Research Institute Lymphoma Clinical Studies Group; Australasian Leukaemia and Lymphoma Group. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). <i>Blood</i>. 2008;112(6):2248-2260. doi:10.1182/blood-2008-03-145128<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/18612102/pubmed" id="18612102" target="_blank">18612102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16484584">
<a name="16484584"></a>Milligan DW, Wheatley K, Littlewood T, et al. Fludarabine and Cytosine are Less Effective than Standard ADE Chemotherapy in High-Risk Acute Myeloid Leukemia, and Addition of G-CSF and ATRA are not Beneficial: Results of the MRC AML-HR Randomized Trial. <i>Blood</i>. 2006;107(12):4614-4622.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/16484584/pubmed" id="16484584" target="_blank">16484584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9625576">
<a name="9625576"></a>Montillo M, Mirto S, Petti MC, et al. Fludarabine, Cytarabine, and G-CSF (FLAG) for the Treatment of Poor Risk Acute Myeloid Leukemia. <i>Am J Hematol</i>. 1998;58(2):105-109.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/9625576/pubmed" id="9625576" target="_blank">9625576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21276754">
<a name="21276754"></a>Morgan C, Tillett T, Braybrooke J, et al. Management of Uncommon Chemotherapy-Induced Emergencies. <i>Lancet Oncol</i>. 2011;12(8):806-814.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/21276754/pubmed" id="21276754" target="_blank">21276754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31787588">
<a name="31787588"></a>Morita K, Ashizawa M, Toda Y, et al. Salvage chemotherapy followed by autologous stem-cell transplantation using targeted busulfan for refractory diffuse large B-cell lymphoma with dialysis-dependent end-stage renal disease. <i>Clin Lymphoma Myeloma Leuk</i>. 2020;20(2):e92-e96. doi:10.1016/j.clml.2019.11.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/31787588/pubmed" id="31787588" target="_blank">31787588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27868581">
<a name="27868581"></a>Neuss MN, Gilmore TR, Belderson KM, et al. 2016 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards, including standards for pediatric oncology<i>. J Oncol Pract</i>. 2016;12(12):1262-1271. doi:10.1200/JOP.2016.017905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/27868581/pubmed" id="27868581" target="_blank">27868581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33951900">
<a name="33951900"></a>Özcan G, Uçakhan ÖÖ. Cytarabine-induced corneal toxicity: clinical features and relief of symptoms with loteprednol etabonate 0.5% in two patients. <i>Turk J Ophthalmol</i>. 2021;51(2):114-117. doi:10.4274/tjo.galenos.2020.99248<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/33951900/pubmed" id="33951900" target="_blank">33951900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29194712">
<a name="29194712"></a>Pallazola VA, Murray JC, Al Harthy M, Zimmerman SL, Webster J, Gondek LP. Anthracycline-induced acute myocarditis and ventricular fibrillation arrest. <i>Am J Hematol</i>. 2018;93(3):469-470. doi:10.1002/ajh.24989<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/29194712/pubmed" id="29194712" target="_blank">29194712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17132719">
<a name="17132719"></a>Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. <i>Blood</i>. 2007;109(7):2773-2780.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/17132719/pubmed" id="17132719" target="_blank">17132719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11369626">
<a name="11369626"></a>Patte C, Auperin A, Michon J, et al. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. <i>Blood</i>. 2001;97(11):3370-3379.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/11369626/pubmed" id="11369626" target="_blank">11369626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30729654">
<a name="30729654"></a>Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: a clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2019;66(5):e27646. doi:10.1002/pbc.27646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/30729654/pubmed" id="30729654" target="_blank">30729654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11176579">
<a name="11176579"></a>Pease CL, Horton TM, McClain KL, et al. Aseptic Meningitis in a Child After Systemic Treatment With High Dose Cytarabine. <i>Pediatr Infect Dis J</i>. 2001;20(1):87-89.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/11176579/pubmed" id="11176579" target="_blank">11176579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11485147">
<a name="11485147"></a>Pegram AA, Kennedy LD. Prevention and Treatment of Veno-Occlusive Disease. <i>Ann Pharmacother</i>. 2001;35(7-8):935-942.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/11485147/pubmed" id="11485147" target="_blank">11485147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17658395">
<a name="17658395"></a>Pieters R, Schrappe M, De Lorenzo P, et al. A Treatment Protocol for Infants Younger Than 1 Year With Acute Lymphoblastic Leukaemia (Interfant-99): An Observational Study and a Multicentre Randomised Trial. <i>Lancet</i>. 2007;370(9583):240-250.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/17658395/pubmed" id="17658395" target="_blank">17658395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26549586">
<a name="26549586"></a>Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. <i>Lancet Oncol</i>. 2015;16(16):1677-1690.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/26549586/pubmed" id="26549586" target="_blank">26549586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20705755">
<a name="20705755"></a>Powell BL, Moser B, Stock W, et al. Arsenic Trioxide Improves Event-Free and Over-All Survival for Adults With Acute Promyelocytic Leukemia: North American Leukemia Intergroup Study C9710. <i>Blood</i>. 2010;116(19):3751-3757.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/20705755/pubmed" id="20705755" target="_blank">20705755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20532508">
<a name="20532508"></a>Radeski D, Cull GM, Cain M, Hackett LP, Ilett KF. Effective clearance of Ara-U the major metabolite of cytosine arabinoside (Ara-C) by hemodialysis in a patient with lymphoma and end-stage renal failure. <i>Cancer Chemother Pharmacol</i>. 2011;67(4):765-768. doi:10.1007/s00280-010-1373-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/20532508/pubmed" id="20532508" target="_blank">20532508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6928748">
<a name="6928748"></a>Rassiga AL, Schwartz HJ, Forman WB, Crum ED. Cytarabine-induced anaphylaxis. Demonstration of antibody and successful desensitization. <i>Arch Intern Med</i>. 1980;140(3):425-426. doi:10.1001/archinte.140.3.425<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/6928748/pubmed" id="6928748" target="_blank">6928748</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7844594">
<a name="7844594"></a>Ribeiro RC, Rivera GK, Hudson M, et al. An intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia. <i>J Clin Oncol</i>. 1995;13(2):333-338. doi:10.1200/JCO.1995.13.2.333<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/7844594/pubmed" id="7844594" target="_blank">7844594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8704238">
<a name="8704238"></a>Rivera GK, Hudson MM, Liu Q, et al. Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia. <i>Blood</i>. 1996;88(3):831-837.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/8704238/pubmed" id="8704238" target="_blank">8704238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15042678">
<a name="15042678"></a>Rizzieri DA, Johnson JL, Niedzwiecki D, et al. Intensive Chemotherapy With and Without Cranial Radiation for Burkitt Leukemia and Lymphoma: Final Results of Cancer and Leukemia Group B Study 9251. <i>Cancer</i>. 2004;100(7):1438-1448.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/15042678/pubmed" id="15042678" target="_blank">15042678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20555089">
<a name="20555089"></a>Roila F, Herrstedt J, Aapro M, et al; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. <i>Ann Oncol</i>. 2010;21(suppl 5):v232-v243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/20555089/pubmed" id="20555089" target="_blank">20555089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16145068">
<a name="16145068"></a>Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. <i>J Clin Oncol</i>. 2005;23(28):7013-7023. doi:10.1200/JCO.2005.01.1825<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/16145068/pubmed" id="16145068" target="_blank">16145068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23569323">
<a name="23569323"></a>Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). <i>J Clin Oncol</i>. 2013;31(25):3061-3068. doi:10.1200/JCO.2012.46.9957<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/23569323/pubmed" id="23569323" target="_blank">23569323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-498009">
<a name="498009"></a>Rudnick SA, Cadman EC, Capizzi RL, Skeel RT, Bertino JR, McIntosh S. High dose cytosine arabinoside (HDARAC) in refractory acute leukemia. <i>Cancer</i>. 1979;44(4):1189-1193. doi:10.1002/1097-0142(197910)44:4&lt;1189::aid-cncr2820440404&gt;3.0.co;2-o<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/498009/pubmed" id="498009" target="_blank">498009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30836786">
<a name="30836786"></a>Sahu KK, Yanamandra U, Malhotra P. Ara-C related red ear syndrome. <i>Ear Nose Throat J</i>. 2019;98(3):169-170. doi:10.1177/0145561319831270<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/30836786/pubmed" id="30836786" target="_blank">30836786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25728956">
<a name="25728956"></a>Sainz de la Maza Cantero S, Jiménez Martín A, de Felipe Mimbrera A, Corral Corral Í. Cerebellar toxicity due to cytarabine: a series of 4 cases. Toxicidad cerebelosa por citarabina: serie de 4 casos. <i>Neurologia</i>. 2016;31(7):491-492. doi:10.1016/j.nrl.2014.12.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/25728956/pubmed" id="25728956" target="_blank">25728956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16947320">
<a name="16947320"></a>Saito B, Nakamaki T, Nakashima H, et al. Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia. <i>Am J Hematol</i>. 2007;82(4):304-306. doi:10.1002/ajh.20772<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/16947320/pubmed" id="16947320" target="_blank">16947320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sandhu.1">
<a name="Sandhu.1"></a>Sandhu G, Adattini J, O’Neill N, et al; Working Group for the International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction. International consensus guideline for anticancer drug dosing in kidney dysfunction (ADDIKD): a standardized approach to assessing kidney function in cancer patients and its application to anticancer drug dosing. <i>J Clin Oncol</i>. Published online June 2, 2022. https://ascopubs.org/doi/pdf/10.1200/JCO.2022.40.16_suppl.e13518?role=tab.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18812465">
<a name="18812465"></a>Sanz MA, Grimwade D, Tallman MS, et al. Management of Acute Promyelocytic Leukemia: Recommendations From an Expert Panel on Behalf of the European LeukemiaNet. <i>Blood</i>. 2009;113(9):1875-1891.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/18812465/pubmed" id="18812465" target="_blank">18812465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20393132">
<a name="20393132"></a>Sanz MA, Montesinos P, Rayón C, et al. Risk-Adapted Treatment of Acute Promyelocytic Leukemia Based on all-trans Retinoic Acid and Anthracycline With Addition of Cytarabine in Consolidation Therapy for High-Risk Patients: Further Improvements in Treatment Outcome. <i>Blood</i>. 2010;115(25):5137-5146.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/20393132/pubmed" id="20393132" target="_blank">20393132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17947720">
<a name="17947720"></a>Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. <i>J Clin Oncol</i>. 2007;25(30):4730-4735. doi:10.1200/JCO.2007.12.5062<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/17947720/pubmed" id="17947720" target="_blank">17947720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9053511">
<a name="9053511"></a>Smith G, Damon LE, Rugo HS, et al. High-Dose Cytarabine Dose Modification Reduces the Incidence of Neurotoxicity in Patients With Renal Insufficiency. <i>J Clin Oncol</i>. 1997;15(2):833-839. doi:10.1200/JCO.1997.15.2.833<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/9053511/pubmed" id="9053511" target="_blank">9053511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8795687">
<a name="8795687"></a>Stasi R, Venditti A, Del Poeta G, et al. High-Dose Chemotherapy in Adult Acute Myeloid Leukemia: Rationale and Results. <i>Leuk Res</i>. 1996;20(7):535-549.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/8795687/pubmed" id="8795687" target="_blank">8795687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8221579">
<a name="8221579"></a>Steinherz PG, Redner A, Steinherz L, Meyers P, Tan C, Heller G. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol. <i>Cancer</i>. 1993;72(10):3120-3130.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/8221579/pubmed" id="8221579" target="_blank">8221579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30658992">
<a name="30658992"></a>Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. <i>Blood</i>. 2019;133(14):1548-1559. doi:10.1182/blood-2018-10-881961<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/30658992/pubmed" id="30658992" target="_blank">30658992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11468148">
<a name="11468148"></a>Stone RM, Berg DT, George SL, et al. Postremission Therapy in Older Patients With <i>de novo</i> Acute Myeloid Leukemia: A Randomized Trial Comparing Mitoxantrone and Intermediate-Dose Cytarabine With Standard-Dose Cytarabine. <i>Blood</i>. 2001;98(3):548-553.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/11468148/pubmed" id="11468148" target="_blank">11468148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19438471">
<a name="19438471"></a>Storring JM, Minden MD, Kao S, et al. Treatment of Adults With BCR-ABL Negative Acute Lymphoblastic Leukaemia With a Modified Paediatric Regimen. <i>Br J Haematol</i>. 2009;146(1):76-85.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/19438471/pubmed" id="19438471" target="_blank">19438471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12627859">
<a name="12627859"></a>Takeuchi M, Yamauchi T, Yoshida I, Soda R, Ueda T, Takahashi K. Pharmacokinetics of a standard dose of cytarabine in a patient with acute promyelocytic leukemia undergoing continuous ambulatory peritoneal dialysis. <i>Int J Hematol</i>. 2003;77(2):196-198. doi:10.1007/BF02983222<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/12627859/pubmed" id="12627859" target="_blank">12627859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23889312">
<a name="23889312"></a>Termuhlen AM, Smith LM, Perkins SL, et al. Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children's Oncology Group. <i>Br J Haematol</i>. 2013;162(6):792-801.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/23889312/pubmed" id="23889312" target="_blank">23889312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16502413">
<a name="16502413"></a>Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. <i>Cancer</i>. 2006;106(7):1569-1580. doi:10.1002/cncr.21776<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/16502413/pubmed" id="16502413" target="_blank">16502413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2299370">
<a name="2299370"></a>Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. <i>J Clin Oncol</i>. 1990;8(2):272-279. doi:10.1200/JCO.1990.8.2.272<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/2299370/pubmed" id="2299370" target="_blank">2299370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trissel.1">
<a name="Trissel.1"></a>Trissel LA, King KM, Zhang Y, et al. Physical and Chemical Stability of Methotrexate, Cytarabine, and Hydrocortisone in Elliott's B Solution for Intrathecal Use. <i>J Oncol Pharm Pract</i>. 2002;8(1):27-32.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12210815">
<a name="12210815"></a>Truica CI, Frankel SR. Acute rhabdomyolysis as a complication of cytarabine chemotherapy for acute myeloid leukemia: case report and review of literature. <i>Am J Hematol</i>. 2002;70(4):320-323.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/12210815/pubmed" id="12210815" target="_blank">12210815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18182662">
<a name="18182662"></a>Tsimberidou AM, Wierda WG, Plunkett W, et al. Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>J Clin Oncol</i>. 2008;26(2):196-203.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/18182662/pubmed" id="18182662" target="_blank">18182662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21298312">
<a name="21298312"></a>Tsuchiya Y, Ubara Y, Suwabe T, et al. Successful treatment of acute promyelocytic leukemia in a patient on hemodialysis. <i>Clin Exp Nephrol</i>. 2011;15(3):434-437. doi:10.1007/s10157-011-0405-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/21298312/pubmed" id="21298312" target="_blank">21298312</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed September 28, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15800666">
<a name="15800666"></a>van Imhoff GW, van der Holt B, MacKenzie MA, et al. Short Intensive Sequential Therapy Followed by Autologous Stem Cell Transplantation in Adult Burkitt, Burkitt-Like and Lymphoblastic Lymphoma. <i>Leukemia</i>. 2005;19(6):945-952.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/15800666/pubmed" id="15800666" target="_blank">15800666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3334893">
<a name="3334893"></a>Velasquez WS, Cabanillas F, Salvador P, et al. Effective Salvage Therapy for Lymphoma With Cisplatin in Combination With High-Dose Ara-C and Dexamethasone (DHAP). <i>Blood</i>. 1988;71(1):117-122.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/3334893 /pubmed" id="3334893 " target="_blank">3334893 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8201379">
<a name="8201379"></a>Velasquez WF, McLaughlin P, Tucker S, et al. ESHAP - An Effective Chemotherapy Regimen in Refractory and Relapsing Lymphoma: A 4-Year Follow-up Study. <i>J Clin Oncol</i>. 1994;12(6):1169-1176.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/8201379 /pubmed" id="8201379 " target="_blank">8201379 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27927586">
<a name="27927586"></a>Visco C, Chiappella A, Nassi L, et al. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. <i>Lancet Haematol</i>. 2017;4(1):e15-e23. doi:10.1016/S2352-3026(16)30185-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/27927586/pubmed" id="27927586" target="_blank">27927586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23401442">
<a name="23401442"></a>Visco C, Finotto S, Zambello R, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. <i>J Clin Oncol</i>. 2013;31(11):1442-1449. doi:10.1200/JCO.2012.45.9842<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/23401442/pubmed" id="23401442" target="_blank">23401442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1607916">
<a name="1607916"></a>Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. <i>J Clin Oncol</i>. 1992;10(7):1103-1111.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/1607916/pubmed" id="1607916" target="_blank">1607916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29941458">
<a name="29941458"></a>Vrooman LM, Blonquist TM, Harris MH, et al. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. <i>Blood Adv</i>. 2018;2(12):1449-1458. doi:10.1182/bloodadvances.2018016584<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/29941458/pubmed" id="29941458" target="_blank">29941458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32219442">
<a name="32219442"></a>Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. <i>Blood</i>. 2020;135(24):2137‐2145. doi:10.1182/blood.2020004856<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/32219442/pubmed" id="32219442" target="_blank">32219442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12209751">
<a name="12209751"></a>Weiss MA, Aliff TB, Tallman MS, et al. A Single, High Dose of Idarubicin Combined With Cytarabine as Induction Therapy for Adult Patients With Recurrent or Refractory Acute Lymphoblastic Leukemia. <i>Cancer</i>. 2002;95(3):581-587.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/12209751/pubmed" id="12209751" target="_blank">12209751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23828018">
<a name="23828018"></a>Wenzell CM, Gallagher EM, Earl M, et al. Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight. <i>Am J Hematol</i>. 2013;88(10):906-909. doi:10.1002/ajh.23530<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/23828018/pubmed" id="23828018" target="_blank">23828018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18076637">
<a name="18076637"></a>Wierzbowska A, Robak T, Pluta A, et al. Cladribine Combined With High Doses of Arabinoside Cytosine, Mitoxantrone, and G-CSF (CLAG-M) is a Highly Effective Salvage Regimen in Patients With Refractory and Relapsed Acute Myeloid Leukemia of the Poor Risk: A Final Report of the Polish Adult Leukemia Group. <i>Eur J Haematol.</i> 2008;80(2):115-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/18076637/pubmed" id="18076637" target="_blank">18076637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1730080">
<a name="1730080"></a>Wiernik PH, Banks P, Case Jr DC, et al. Cytarabine Plus Idarubicin or Daunorubicin as Induction and Consolidation Therapy for Previously Untreated Adult Patients With Acute Myeloid Leukemia. <i>Blood</i>. 1992;79(2):313-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/1730080/pubmed" id="1730080" target="_blank">1730080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24297940">
<a name="24297940"></a>Willemze R, Suciu S, Meloni G, et al. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. <i>J Clin Oncol</i>. 2014;32(3):219-228. doi:10.1200/JCO.2013.51.8571<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/24297940/pubmed" id="24297940" target="_blank">24297940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8426204">
<a name="8426204"></a>Winick NJ, Smith SD, Shuster J, et al. Treatment of CNS relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study. <i>J Clin Oncol</i>. 1993;11(2):271-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/8426204/pubmed" id="8426204" target="_blank">8426204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wittbrodt.1">
<a name="Wittbrodt.1"></a>Wittbrodt ET, Aviles VM. Pancreatitis and Fatal ARDS Following High-Dose Cytarabine Induction for Acute Myelogenous Leukemia. <i>J Oncol Pharm Pract</i>. 1997;3(2):110-115.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10198745">
<a name="10198745"></a>Woods T, Vidarsson B, Mosher D, Stein JH. Transient effusive-constrictive pericarditis due to chemotherapy. <i>Clin Cardiol</i>. 1999;22(4):316-318. doi:10.1002/clc.4960220414<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/10198745/pubmed" id="10198745" target="_blank">10198745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2205352">
<a name="2205352"></a>Woods WG, Ruymann FB, Lampkin BC, et al. The Role of Timing of High-Dose Cytosine Arabinoside Intensification and of Maintenance Therapy in the Treatment of Children With Acute Nonlymphocytic Leukemia. <i>Cancer</i>. 1990;66(6):1106-1113.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/2205352/pubmed" id="2205352" target="_blank">2205352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12930315">
<a name="12930315"></a>Wrzesień-Kuś A, Robak T, Lech-Marańda E, et al. A Multicenter, Open, Non-Comparative Phase II Study of the Combination of Cladribine (2-Chlorodeoxyadenosine), Cytarabine, and G-CSF as Induction Therapy in Refractory Acute Myeloid Leukemia – A Report of the Polish Adult Leukemia Group (PALG). <i>Eur J Haematol</i>. 2003;71(3):155-162.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/12930315/pubmed" id="12930315" target="_blank">12930315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32871908">
<a name="32871908"></a>Yang QJ, Zheng J, Dang FT, Wan YM, Yang J. Acute pancreatitis induced by combination chemotherapy used for the treatment of acute myeloid leukemia: a case report. <i>Medicine (Baltimore)</i>. 2020;99(35):e21848. doi:10.1097/MD.0000000000021848<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cytarabine-conventional-pediatric-drug-information/abstract-text/32871908/pubmed" id="32871908" target="_blank">32871908</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13197 Version 306.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
